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Major Professor: Susan C, Kandarian, Ph .D., Professor of Health Sciences 
ABSTRACT 
NF-KB plays a central role in regulating skeletal muscle atrophy. We 
previously showed that a NF-KB transcription factor p50 and its transcriptional co-
activator Bcl-3 are both required for inducing muscular disuse atrophy due to 
hind limb unloading in a mouse model. However, less is known about the 
molecular mechanisms of the atrophy-resistant phenotype seen in nfkbr'- (lack 
of p50 protein) and bc/-3_,_ mice. The purpose of this study is to identify genes 
that are targets of p50 and Bcl-3 in unloading atrophy at a genome-wide level. 
Global gene expressions of plantar flexor muscles was first measured from wild-
type, nfkbr'- and bc/-3_,_ mice with or without 6 days of hind limb unloading. 
Genes that were upregulated in wild-type mice due to unloading but not in the 
knockout mice were considered p50 or Bcl-3 direct or indirect target genes. 185 
p50 and 240 Bcl-3 target genes were identified in disuse atrophy, and most of 
these genes encoded proteins involved in proteolysis and transcriptional 
regulation. All p50 target genes were also identified as Bcl-3 targets. Direct Bcl-
3 binding targets in unloading atrophy were identified using ChiP-sequencing. In 
atrophied muscles there was an increase in Bcl-3 binding to the promoter regions 
vi 
of genes encoding E3 ligases, N-end rule proteins, kinase and glycolysis 
enzymes. By studying the expression changes of Bcl-3 binding targets, a Bcl-3 
regulated gene network that is responsible for processes underlying unloading 
atrophy was mapped. One Bcl-3 direct target in unloading atrophy, Muscle 
specific Ring finger protein 1 (MuRF1 ), was studied in detail by qPCR, ChiP-
seq, and MuRF1 promoter-reporter assays. These results provided the first 
direct evidence that the p50 and Bcl-3 bind to NF-KB binding sites to 
transactivate MuRF1 during muscle atrophy. Taken together, our data support 
Bcl-3 as a global regulator of genes involved in the proteolysis and the change in 
energy metabolism that are essential components of muscle atrophy due to 
disuse. 
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Chapter 1 NF-KB plays a central role in regulating atrophy processes during 
skeletal muscle atrophy 
1.1 Introduction 
Skeletal muscle is the major depot of protein in the body. Muscle mass is 
maintained in a dynamic balance between protein synthesis and degradation 
which is sensitive to adjustments in biomechanicalloading , nerve activity, 
nutritional status, or stimuli from hormones, growth factors, or cytokines. In 
response to disuse, denervation, chronic disease states, inflammation or 
corticosteroid hormone treatment, skeletal muscle loses mass, a process known 
as atrophy. Depending on the atrophy trigger, different signaling pathways are 
activated to alter muscle protein turnover. In this dissertation I focused on 
studying the molecular control of disuse atrophy, specifically hind limb unloading-
induced skeletal muscle atrophy. Other types of disuse atrophy such as chronic 
bed resting, limb casting , mechanical ventilation , or removal of gravity (i.e. , space 
flight) are mechanistically comparable in the mechanical input trigger that 
activates signaling pathways (1 ,2). Atrophy triggers such as inflammation or 
catabolic hormones activate different signaling pathways (1). 
Muscle atrophy is characterized by a reduction in muscle fiber size with no 
change in fiber number. The rate of muscle atrophy occurs quickly within the first 
2 weeks of disuse stimuli and slows down gradually after 30 days (3) . In our lab, 
30-45% loss in soleus muscle cross sectional area (CSA) from mice and rats was 
observed after 7 days of unloading (4 ,5). In rats, an average loss of 0.6% soleus 
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muscle CSA per day has been estimated in the first 30 days of hind limb 
unloading (3) , whereas loss in total protein content have been reported to occur 
at a higher rate (3% per day) in soleus muscles following 2-15 days of spinal cord 
isolation (2). Several groups have reported a preferential loss in myofibrillar 
protein relative to total protein (2 ,6,7) . A faster loss of slow fibers relative to fast 
fibers is also well documented in disuse atrophy (3). 
1.2 Cellular and molecular adaptations due to disuse atrophy 
1.2.1 Blunted protein synthesis and development of anabolic resistance in 
disuse atrophy 
Attenuated protein synthesis is well supported in both animal and human 
models of disuse atrophy. In rat soleus muscles, -50% repression in protein 
synthesis (measured in fasted state) was observed as early as 1 day after hind 
limb unloading and remained repressed for at least 7 days (8) . In human 
quadriceps muscles, 10 days of immobilization induced a 50% repression in 
myofibrillar fractional protein synthesis which persisted for at least 21 days (9) . 
Indeed, several key regulators in translational initiation such as the AkU mTOR 
pathway, have been reported to be altered due to disuse. In rat gastrocnemius 
muscles, a marked decrease in the phosphorylated state of Akt (pS473) or 
mTOR (pS2448) and p70S6K total protein expression were observed following 
14 days of hind limb unloading (10, 11 ), and this was accompanied by increased 
4E-BP1 binding to the eukaryotic initiation factor eiF-4E that inhibit translational 
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initiation (1 0). A similar trend was observed in human diaphragm muscles where 
decreased Akt phosphorylation was found in nuclear fractions of muscles that 
underwent mechanical ventilation (12) . However, the downregulation in Aktl 
mTOR/ p70S6K signaling due to unloading has been shown to be diminished 
with prolonged muscle disuse in rat (13). These data suggest that repressed 
translational signals is re-activated by prolonged disuse a compensatory 
response to muscle loss. 
In addition to attenuated protein synthesis, disuse also causes a deficit in 
protein synthesis capacity of muscle in response to the increased availability of 
amino acids, which is known as anabolic resistance. In young healthy human 
subjects, atrophied quadriceps due to 14 days unloading showed blunted 
myofibi-illar protein synthesis in response to both low and high doses of amino 
acid infusion compared to weight-bearing muscles (14). This was associated 
with decreased phosphorylation of a putative tension-sensing protein, FAK, in the 
atrophied unloaded leg (14). It was proposed that disuse induced repression of 
protein synthesis and development of anabolic resistance were responsible for 
muscle atrophy (14) . 
1.2.2 Increased protein degradation rate in disuse atrophy 
Marked elevation in protein breakdown had been reported in disuse 
atrophy (15). In skeletal muscle atrophy, the loss of muscle protein has been 
directly correlated with the activation of four proteolytic systems: calcium-
dependent calpain, caspase-3, lysosomal cathepsin-based autophagy and 
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ubiquitin-dependent proteasomal degradation. However the degree to which 
each system contributes to disuse atrophy is equivocal. Following hind limb 
suspension, resting cytosolic Ca2+ homeostasis is significantly disturbed which 
can start as early as 2 days and lasts for at least 14 days (16, 17). Interestingly, 
reduction in single fiber peak isometric tension and loss of titin and nebulin 
content induced by unloading was attenuated in the presence of the calcium 
chelator, EGTA (18) . These data indicated the importance of calcium-dependent 
proteases in disuse atrophy. Calpains are calcium-activated cysteine proteases 
that have been reported to bind to a-actinin at Z-discs for initiating digestion of 
titin, nebulin , desmin , tropomyosin , etc. in vitro (19). Calpain2 mRNA expression 
and enzyme activity were increased in atrophied rat tibialis anterior following 9 
days of unloading (15). Increased total calpain activity was also observed in 
mouse gastrocnemius muscles following 12hr, 24hr, and 7 days of unloading 
(20) . Importantly, Talbert et a/.(21) showed that reductions in type I and type I lA 
soleus myofiber GSA due to 7 days of immobilization were reversed by 
concurrent administration of calpain inhibitor SJA-6017, further demonstrating the 
requirement of calpain for inducing disuse-induced muscle atrophy. 
Caspases are a family of cysteinyl proteases that play a critical role in the 
execution of apoptosis. In serum-deprived L6 muscle cells, caspase-3 has been 
found to initiate actomyosin breakdown and facilitate ubiquitin-dependent 
proteasomal degradation (22) . Caspase-3 activity was shown to be upregulated 
early in response to unloading atrophy and returned to normal level 48 hours 
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after unloading (23). However, Bruusgaard eta/. (24) showed that the number of 
myonuclei per myofiber remained constant following 2, 4, and 14 days of 
unloading. Apoptosis induced by unloading was confined to the nuclei outside of 
the muscle fibers , mainly occurred in stroma cells (24). Therefore, the 
importance of caspase activation for inducing muscle atrophy due to unloading 
remained controversial. 
Autophagy, also known as lysosomal enzyme-mediated protein 
degradation, is reported to be the major proteolytic pathway in fasting or 
denervation induced muscle atrophy (25,26). In response to unloading, there 
were increased lysosomal enzyme activities in unloaded atrophied rat soleus 
muscles with an associated upregulation in cathepsin Band cathepsin L mRNA 
expression (15). However, the substrates of cathepsins in muscle unloading are 
not known and it is not understood how cathepsins degrade myofibril proteins at 
a neutral pH in the cytoplasm. One in vivo study showed that administration of 
chloroquine , a lysosomotropic agent, attenuated muscle atrophy in the 
denervated muscles but not in the unloaded muscles, indicating that lysosomal 
proteolysis may not play an important role in protein degradation for unloading-
induced muscle atrophy (27). 
ATP-dependent ubiquitin proteasome degradation is the major proteolysis 
system for increased protein degradation in atrophying soleus due to unloading 
(15). Most protein substrates degraded by this process are first marked by 
covalent linkage to ubiquitin in a multi-enzyme pathway. This ubiquitylation 
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process is illustrated in Figure 1.1. Protein ubiquitination via lysine-48 linked 
chains leads to proteolysis in the proteasome. Components of the ubiquitin 
proteasome degradation pathway were shown to be actively synthesized during 
disuse including ubiquitin , 14kDa E2 (E214K), several E3 ligases and proteasome 
subunits etc. (15,20,28). Much attention has been focused on E3 ligases due to 
their importance for providing substrate specificity. Three candidates thought to 
be important players in disuse atrophy are MuRF1, atrogin-1 (Fbxo32) and Ubr1. 
MuRF1 (or Trim63) is a muscle-specific E3 ligase whose expression is 
induced in multiple animal models of atrophy including disuse, fasting, diabetes, 
sepsis, cancer cachexia, and denervation as well as acute lung injury associated 
muscle wasting in humans (29). Mice null for MuRF1 showed a 36% sparing of _. 
muscle mass following denervation (30). MuRF1 has been shown to be the E3 
ligase required for the degradation of myosin light chain 2 (MyLC2) and myosin 
binding protein C (MyBP-C) (31 ). However, it is important to note that a recent 
study showed upregulated proteasome activity in MuRF1-null mice following 
denervation (32). Muscles from mice containing a knock-in of dominant negative 
RING finger MuRF1 domain (~R-MuRF1) showed reduced muscle atrophy and 
total ubiquitin conjugates in response to denervation atrophy compared to wild-
type littermates; however, a significant reduction in muscle mass and 
upregulated ubiquitin level could still be observed in ~R-MuRF1 mice following 
denervation (31). These recent data suggest that MuRF1 is responsible for 
targeting a specific set of substrates for degradation but its requirement for 
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disuse atrophy remains to be studied . In disuse atrophy, increased MuRF1 
mRNA expression has been reported in hind limb unloading (28) , immobilization 
(33), and mechanical ventilation (34). In both mouse and rats , MuRF1 mRNA 
expression was upregulated early in the unloaded muscles, peaked at the 4-ih 
day and returned to baseline on the 14th day [(35) and unpublished data]. This 
suggested a role for MuRF1 in the early disuse atrophy process. No studies 
have analyzed the MuRF1 protein expression or activity following disuse atrophy. 
Finally, some studies showed that NF-KB (36) , myogenin (37) , glucocorticoid 
binding element and FoxO binding sites (38) were important for MuRF1 
activation in atrophy models other than disuse (reviewed in Chapter 5). 
Atrogin-1 (also known as Fbxo32 or MAFbx) is a member of Skp1, Cullin1 
and Fbxo (SCF) containing protein complex which bind together to establish its 
E3 ubiquitin ligase activity. Consistent increases in atrogin-1 mRNA expression 
have been observed in multiple models of muscle atrophy including disuse (28) , 
fasting (39) , diabetes, sepsis, cancer cachexia (40) , and denervation (30). To 
date, little is known about the functional role of atrogin-1 in skeletal muscle. 
Strong evidence showing the importance of atrogin-1 in atrophy came from a 
study for atrogin-1 knockout mice, a 56% sparing of muscle mass loss following 
14 days of denervation (30) . However, the same group of investigators recently 
reported increased necrosis and appearance of vacuoles in muscles from 
atrogin-1 knockout mice following 28 days of denervation (32). In the context of 
disuse atrophy, upregulated atrogin-1 mRNA expression was found in muscle 
atrophy by space flight (41 ), immobilization (33), mechanical ventilation (34) and 
hindlimb unloading (28) . Regulation of atrogin-1 activation is associated with 
activated PI3K!Aktl FoxO (39) and C/EBP~ (40) in inflammation-associated 
atrophy models. 
8 
Ubr1 gene encodes the enzyme ubiquitin-protein ligase 3 component n-
recognin 1. In theN-end rule pathway, which is one of the proteolytic pathway in 
the ubiquitin system, Ubr1 selectively recognizes protein substrates that contain 
destabilizing basic or large hydrophobic amino acids at their N-termini. In rat, 
rabbit and presumably in other mammals, E214K /Ubr1 functions as the major 
E2/E3 pair for catalyzing ubiquitin conjugation to endogenous proteins in soluble 
extracts of skeletal muscle (42). While the N-end rule was reported to be 
activated in atrophied muscles from septic, cachectic or diabetic animals, its role 
and regulation in disuse atrophy remains to be determined. 
1.3 Roles of NF-KB signaling proteins and transcription factors in 
muscle atrophy 
Nuclear factor kappa B (NF-KB) is a transcription factor family first 
identified for its importance for activating kappa light chain genes in B cells. 
Dimers of NF-KB bind to DNA KB sites to regulate transcription of target genes 
and affect a wide variety of biological processes (43,44). There are five 
mammalian NF-KB transcription factors: p65, ReiB, c-rel, p50 (encoded by 
nfkb1), and p52 (encoded by nfkb2); each contains a Rei-homology domain 
(RHO) enabling dimerization and DNA binding. Distinct structural features of 
each Rei proteins and various KB homodimeric or heterodimeric complexes 
confer the transactivation specificity, which is cell type- and stimulus-dependent. 
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NF-KB activation is tightly regulated by inhibitor of NF-KB (IKB) family 
members: IKBa, IKBI3, IKBy, IKB£, Bcl-3, p1 05 and p1 00 (45). In unstimulated, 
non-diseased state, IKBa retains the prototypical NF-KB heterodimer, p65/p50, in 
cytoplasm. In response to a wide variety of inflammatory stimuli such as 
cytokines (e.g. TN F-a, IL-1 ), ligands for Toll-like receptors (e.g. LPS) or T-cell 
receptor, a signal cascade is activated that results in activation of IKB kinase 
(IKKs) complexes. Activated IKKI3 phosphorylates IKBa which targets IKBa for 
polyubiquitination and subsequent proteasomal degradation. This releases 
p65/p50 heterodimers into the nucleus which bind to KB elements (5'-GGGRN W 
YYCC-3') of target genes where transcriptional activation or repression of KB 
target genes occurs. 
Bcl-3 is a unique IKB family protein that localizes to the nucleus where it 
preferentially binds with p50 and p52 homodimers (46,47). It contains two 
transactivation domains flanking its central 7 ankyrin repeats. Bcl-3-mediated 
regulation of NF-KB activity occurs directly by direct association with p50 and p52 
homodimers on enhancers or promoters of target genes (46,48,49), or indirectly 
by recruitment of other nuclear co-regulators to the existing KB dimers (50-52). 
Bcl-3 regulation of transcription is further complicated by the posttranslational 
modulation of Bcl-3 (e.g., phosphorylation and ubiquitination) (52) or by binding 
with other non-NF-KB transcription factors (e.g., STAT1 , RXR, AP-1 , PGC1a, 
ERRa) (50,53-55). 
10 
NF-KB signaling has been shown to be activated in multiple models of 
skeletal muscle atrophy including but not limited to unloading (56,57), 
immobilization (33), denervation (58) , diabetes (59), inflammation (60), and 
cancer (36). In both mice and rats, increased NF-KB-dependent reporter activity 
was observed in both plantaris and soleus muscles following 3-1 0 days of 
unloading (4,56). In rat soleus, NF-KB-dependent reporter activity increased 2-5 
fold following 3-7 days of cast immobilization (33) . A 4-fold increase in NF-KB-
dependent reporter activity was also observed in diaphragm atrophy induced by 
24-hours of intratracheal infusion of lipopolysaccharide (60) . In other works, 
increased nuclear protein binding to NF- KB oligonucleotides was observed in 
unloaded muscles (4), denervation (36) , sepsis (61) or Lewis lung carcinoma 
(LLC) tumor inoculation (36). 
Inhibition of NF-KB signaling proteins by pharmacological or genetic 
approaches has been shown to ameliorate muscle atrophy resulting from disuse 
(5,62,63), denervation (36,58), inflammation (60,64)and cancer cachexia (36,65) . 
For example, an -50% sparing of myofiber size was observed in rat soleus 
muscle transfected with kinase dead IKKr3 (dominant negative IKKr3) following 
unloading- or immobilization- induced atrophy (5 ,62). In muscle-specific IKKr3 
knockout mice, muscle atrophy induced by 28 days of denervation was 
attenuated by 5-30%. Interestingly, muscle mass sparing was more significant in 
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the oxidative muscle groups compared to glycolytic muscle groups (58) . Others 
found that atrophy due to denervation or LLC tumor bearing was attenuated in 
transgenic mice over-expressing a non-degradable IKBa super repressor 
(IKBaSR) (36). Similar to these results, our lab found that the IKBaSR inhibited 
42% soleus muscle atrophy induced by unloading (66). However, it should be 
noted that NF-KB transcriptional activity and NF-KB signaling ar~ not always 
tightly linked (45) . Recent studies showed that NF-KB signaling proteins such as 
IKKa or IKK~ regulate many non-NF-KB substrates (45), therefore, attenuation of 
muscle atrophy via inhibition of NF-KB signaling proteins could be acted through 
an NF-KB-independent pathway. For example, C-26 tumor inoculation induced 
muscle atrophy was significantly attenuated by 68% in muscles overexpressing 
kinase-dead IKK~, yet no activation of the NF-KB dependent reporter, which 
contained 3 NF-KB sites, was observed in atrophied muscles with C26 tumor 
inoculation (45) . 
The importance of the NF-KB signaling proteins in muscle atrophy is 
further complicated by the fact that NF-KB signaling protein knockout altered 
myofiber type and that NF-KB family members demonstrated a tissue-specific 
expression upon atrophy stimuli. For example, muscle-specific IKK~ knockout 
mice showed an increased number of intermediate fibers in soleus muscles 
compared to wild-type mice, however, such a fiber type change was not 
observed in extensor digitorum longus (EDL) muscles (58). On the other hand, 
soleus muscles from whole body Bcl-3 knock-out mice showed a lower 
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percentage of myofibers stained with fast myosin heavy chain (fMHC) compared 
to that from the wild-type mice, indicating a shift of slow-to-fast myofiber type 
(56). Examples of selective activation of NF-KB dimers in a tissue-specific 
manner were observed in diabetes and disuse induced muscle atrophy. Upon 
diabetic stimuli, an increased level of Bcl-3 was measured in gastrocnemius 
muscles but not in soleus muscles, and a decreased Bcl.:.3 level was measured in 
plantaris muscles (59) . In the same study, increased p65 and p52 content were 
observed in atrophied diabetic muscles whereas no changes in p50 and ReiB 
contents were observed . In contrast, p50 activation is important for mechanical 
ventilation induced diaphragm muscle atrophy where increased p50 DNA-binding 
activity was observed in atrophied diaphragm compared to healthy muscles (63). 
Taken together, these data show that NF-KB signaling appears to be 
activated and required for muscle atrophy elicited by disuse and other illness, the 
importance of which may be muscle type specific and unique to the atrophy 
triggers. In most muscle atrophy models, the activation of specific NF-KB dimers 
downstream of the activated NF-KB signaling proteins have not been determined , 
except for disuse muscle atrophy, which will be discussed below. 
1.4 Requirement of p50 and Bcl-3 in disuse muscle atrophy 
Since NF-KB signaling is required for disuse muscle atrophy, past 
members of our lab focused on identifying transcription factors in the NF-KB 
family that are responsible for the upregulated NF-KB activity in disuse atrophy 
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(4,56,66). Hunter eta/. (4) found increased nuclear p50 and c-rel protein levels 
in unloaded muscles compared to weight-bearing muscles, whereas nuclear 
levels of other NF-KB transcription factors were either decreased or not changed . 
In whole muscle lysates, increased Bcl-3 expression was found in unloaded 
muscles compared to weight-bearing muscles. Gel supershift assays showed 
that the nuclear binding complexes to NF-KB oligonucleotides in unloaded 
muscles contained p50, c-rel and Bcl-3, suggesting that pathways involving p50, 
c-rel, and Bcl-3 are responsible for the upregulated NF-KB activity in disuse 
atrophy. By characterizing the unloading response in c-rel knockout mice, Judge 
eta/. (66) showed that c-rel was not responsible for the upregulated NF-KB 
activity in disuse atrophy. This is based on the fact that both c-rel knockout and 
wild-type mice showed similar degrees of myofiber atrophy, NF-KB-dependent 
reporter activation, and total ubiquitinated protein with unloading. 
Using p50 and Bcl-3 knockout mice (nfkbr'- or bc/3-1-) , Hunter and 
Kandarian (56) showed that upregulated NF-KB-dependent reporter activity due 
to unloading in wild-type mice was abolished in p50 or Bcl-3 knockout mice. 
Consistent with this, 10 days of unloading did not induce significant muscle 
atrophy (measured by fiber cross sectional area) in soleus from p50 or Bcl-3 
knockout mice. The inhibition of NF-KB dependent reporter activity and 
attenuated muscle atrophy in mice with a knockout of either gene following 
unloading as well as the increased nuclear KB oligo binding complex containing 
p50 and Bcl-3 in atrophied muscles suggest that both p50 and Bcl-3 are required 
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for disuse atrophy. We do not have direct evidence supporting a p50/ Bcl-3 
complex during unloading, however, abolished NF-KB dependent reporter activity 
due to unloading in either knockout suggests that p50 and Bcl-3 function 
coordinately. Several lines of evidence have shown that Bcl-3 binds to p50 in a 
complex to activate target gene expression. In a nasopharygeal carcinoma 
tumor cell line, Bcl-3 and p50 have been shown to complex and bind to KB sites 
of the egfr promoter to activate EGFR expression in response to Epstein-Barr 
virus latent membrane protein 1 (48,67). In anaplastic large-cell lymphomas 
(ALCLs), increased NFKB DNA binding activity and upregulated Bcl-3 target gene 
expression were correlated with increased nuclear Bcl-3 and p50 levels as well 
as co-immunoprecipitation of the two proteins (68). In mouse splenocytes, 
estrogen-activated NFKB-dependent reporter activity was correlated with 
increased nuclear Bcl-3, enhanced p50 homodimer nuclear translocation, and 
co-occupancy of Bcl-3 and p50 at the iN OS promoter, which suggested that Bcl-3 
and p50 were in a complex to activate target gene expression (69). 
Interestingly, fiber type immunostaining of the atrophy-resistant soleus 
from p50 or Bcl-3 knockout mice showed a significant inhibition of type II a/ lib · 
myofiber atrophy following unloading compared to wild-type mice, whereas 
inhibition of type I myofiber atrophy was observed in Bcl-3 knockout mice but not 
p50 knockout mice (56) . This observation is consistent with the immunological 
phenotype presentations in knockout mice; p50 and Bcl-3 knockout mice share 
many similarities in response to pathogenic challenges, however, some 
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immunological defects were present in one gene knockout but not the other (70). 
Therefore, we cannot rule out that Bcl-3 functions independently of p50 to 
regulate atrophy genes. 
1.5 Conclusion 
Our lab previously reported that activation of NF-KB, specifically provided 
by Bcl-3 and p50 complexes, are required for disuse atrophy, however, we do not 
know the downstream effectors of Bcl-3 or p50 that induce atrophy nor the 
molecular mechanisms of this process. The purpose of this dissertation is to 
identify the target genes of p50 and Bcl-3 that are driving atrophy processes due 
to unloading. 
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Figure 1.1 A schematic illustration of the three major muscle protein degradation 
pathways during disuse atrophy. Upon atrophy triggers, calpain and caspase 
proteolytic systems are activated to break intact myofiber into smaller dissociated 
myofilaments. The ATP-dependent ubiquitin/ proteasome is responsible for the majority 
of muscle protein degradation during disuse atrophy. In this multiple enzyme process, 
ubiquitin-activating enzyme (E1) activates ubiquitin (Ub) by using ATP to synthesize 
ubiquitin C-terminus adenylate, which then serves as an enzyme-bound substrate for the 
formation of an E1-ubiquitin thioester complex. The latter ubiquitin is transferred to the 
active site cysteine of ubiqutin-conjugating enzyme (E2) via a transthioesterification 
reaction. The E2-ubiqitin thioester next interacts with an E3 ubiquitin ligase, which 
catalyzes the transfer of ubiquitin from the E2 to a lysine residue of a protein substrate. 
Acquiring additional ubiquitins on a protein substrate via lysine-48 linkage typically 
directs the protein to the proteasome for degradation. 
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Chapter 2 Materials and methods 
2.1 Animals and hind limb unloading 
For microarray experiments, six week-old male wild-type mice 
(B6129PF2/J) and age/sex matched Nfkb1-/- mice (B6;129P2-Nfkb1tm1Bai/J) 
and Bcl3-/- mice (FVB; 129P2-Bcl3tm1Ver/J) were purchased from the Jackson 
Laboratory (Bar Harbor, ME). The B6129PF2/J strain used as wild-type has all 
of the 129 background which was part of the knockout cloning and insertion (the 
embryonic stem cell background) for each of these mutants. For ChiP assay and 
ChiP-sequencing experiments, 7-week-old female wild-type mice (C57BU6J) 
were purchased from the Jackson Laboratory (Bar Harbor, ME). Animals were 
provided with chow and water ad libitum and housed individually in the Boston 
University Animal Care Facility. After 3 days of acclimation, mice were randomly 
assigned to weight-bearing (WB) or hind limb unloaded (HU) groups. Mice in the 
HU group had their hind limbs elevated off the cage floor for 5-6 days to induce 
unloading muscle atrophy. The fifth to sixth day of unloading is a key point in the 
atrophy process based on a large volume of literature, and in particularly based 
on a previous time course study we performed on unloaded rat soleus muscle 
[18]. The HU was performed using the methods that we have previously 
published [39] with slight modifications for the mice. Briefly, mice were lightly 
anesthetized with ketamine/xylazine (40mg/kg ;5mg/kg , i.p.). A strip of adhesive 
foam pad (ALIMED Inc, MA) was folded in half and the adhesive surface was 
loosely applied longitudinally along the proximal 2/3 of the tail. Elastic tape 
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(Eiastoplast, Medco Supply Co., NY) was wrapped circumferentially around the 
adhesive foam. A wire was passed through the folded end of the adhesive foam 
pad and then was drawn up to a pulley attached to a 360° swivel hook at the top 
of the cage. The cage walls were extended in height by 10 inches of Plexiglas 
on 4 sides to allow room for the vertical suspension . The length of the wire was 
adjusted so that the toes of the hind limbs touched the cage floor only during full 
hind limb extension. 
For reporter activity measurements, 7 -week-old female Wistar rats from 
Charles River Lab (Wilmington , MA) were used. The use of animals in this study 
was approved by the Institutional Animal Care and Use Committee of Boston 
University (protocol number 12-012). 
2.2 Total RNA isolation, eDNA synthesis and qPCR 
Gastrocnemius and plantaris muscles harvested from anesthetized wild-
type mice from control and HU groups were snap frozen in liquid nitrogen and 
stored at -80°C before use. Total RNA was extracted using the Qiagen 
miRNeasy Mini kit (Valencia, CA) according to the manufacturer's instructions. 
Extracted total RNA was treated with RNase-Free DNase I (Qiagen , Valencia, 
CA) to remove DNA contamination and purified using an RNeasy Mini kit 
(Qiagen , Valencia , CA) as previously described [40]. Total RNA was quantified 
by absorption spectrophotometry at 260 and 280nm and the quality of total RNA 
was assessed on a 1% denaturing agarose gel and by a Bioanalyzer 2100 
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(Agilent, Palo Alto, CA). 
Total RNA from three strains of mice (two knockouts and one wild-type) 
for two conditions (WB and HU) was isolated as described above. Five IJg of 
total RNA was reverse transcribed in a 1 OOIJI reaction using a High Capacity 
eDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according 
to the manufacturer's instructions. Synthesized eDNA (0.9 IJI) was then amplified 
with the Taqman Gene Expression Master mix, and gene-specific TaqMan Gene 
Expression Assay Buffer (Applied Biosystems). The sequence targeted by each 
TaqMan probe is given in Table S3. Amplification was performed by an ABI 
7300 Real-Time PCR System at the following temperatures: sooc for 2m in , 95oc 
for 1Om in, followed by 40 cycles at 95°C for 15sec and 60oc for 1 min. All 
samples were run in triplicate and quantified according to the corresponding 
gene-specific standard curves. Gene expression values were quantified by 
comparing Cr values of the unknown sample to the gene-specific standard curve. 
Each gene was normalized to GAPDH expression , which was not different due to 
mouse strain or to hind limb unloading . 
2.3 Microarray and data analysis 
For identifying Bcl-3 and p50 direct or indirect target genes (in Chapter 4) , 
24 mice were used based on 4 mice per group, 3 mouse stains (wild-type, bc/3_1_, 
and nfkbr1-) and 2 conditions (weight-bearing and unloaded). Total RNA 
samples (n=4 per group) were sent to Partners HealthCare Center for 
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Personalized Genetic Medicine for mRNA labeling, hybridization, and scanning 
using the Affymetrix system (Santa Clara, CA). In brief, double-stranded eDNA 
was synthesized by GeneChip® Two-Cycle eDNA Synthesis Kit (P/N 900432). 
Biotin-labeled cRNA was then generated and purified by GeneChip IVT labeling 
kit (P/N 900449) and cRNA Cleanup kit (P/N 900547). Fifteen microgram of 
labeled fragmented cRNA was hybridized on to Affymetrix GeneChip Mouse 
Genome 430A 2.0 Array, then washed and stained according to manufacturer's 
protocol. The 430A 2.0 Array measures expression levels of 14,000 
characterized genes. The microarray slides were scanned using a GeneChip® 
Scanner 3000. For data extraction and quality control, Affymetix GeneChip® 
operation software was used, which created a single intensity value for each 
probe-set assayed in each sample in a .eel file. Data files were deposited into 
the MIAME-compliant NCBI Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/), accession number GSE23497. Affymetrix 
.eel files were imported into GenePattern software 3.2.1 (Broad Institute, 
Cambridge, MA) and a matrix containing an expression value per probe set for 
each sample was generated by Expression File Creator Module using the Robust 
Multi-array Average (RMA) algorithm and quantile normalization [41 ]. Gene 
probes were filtered according to the following criteria: maximum expression 
value/ minimum expression value ;:::1.7, minimum expression variation (maximum 
value- minimum value) ;:::9, expression value greater than 20 or less than 20,000. 
Genes complying with these criteria were further processed by the 
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ComparativeMarkerSelection Module Version?. By default, 
ComparativeMarkerSelection compared the mean difference in gene expressions 
between weight-bearing and unloaded muscle samples using two-way 
parametric t-tests and computed false discovery rate for each probe set using the 
Q-value [42]. P-value :5 0.05 and q-value :5 0.05 were used to identify genes that 
were significantly differentially expressed after hind limb unloading. We also 
carried out gene expression analyses for the wild-type vs. knockouts in the 
weight-bearing condition as a control for any change in gene expression that 
might arise from the knockout itself. We found no significant differences in 
muscle gene expression in wild-type vs. Bcl3-'-, but 17 genes in the Nfkbr'- case 
were lower than wild-type. Only one of those 17 was in our list of genes that 
could be a target of p50 and so this gene (Myh?) was removed from our results . 
For profiling expression changes in muscles from wild-type mice following 
5 days of unloading (Chapter 5) , the whole-genome gene expression profiling 
was carried out by the Boston University Microarray Core Facility. Each group 
(control and unloaded) included 4 independent total RNA samples with a minimal 
RIN number 8.0 verified by Bioanalyzer 2100 (Agilent Technology, Palo Alto, 
CA). Each total RNA sample was amplified , labeled , and hybridized on a 
Affymetrix Mouse Gene 1.0 ST array (Santa Clara, CA) per the manufacturer's 
instructions to measure expression of 28,853 well-annotated genes. A total of 8 
array images were acquired by GeneChip Scanner 3000 7G and the quality was 
assessed by Affymetrix Expression Console (Santa Clara , CA) . Gene 
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expression signals were generated by robust multi-array analysis (RMA) (71) 
using Brainarray MoGene 1.0ST custom CDF files (72). Differential gene 
expression was computed using the Comparative Marker Selection module in 
Genepattern database (Broad Institute, Cambridge, MA) which compares mean 
differences between control and unloaded groups by two-way parametric t-test. 
P-value :5 0.05 and q-value :5 0.05 were used to identify genes that were 
significantly differentially expressed with hind limb unloading. The microarray 
data reported in the chapter 5 have been deposited in the NCBI Gene 
Expression Omnibus (GEO) with accession no. GSE40578. 
2.4 Chromatin immunoprecipitation-PCR (ChiP-PCR), ChiP-sequencing 
and data processing 
For ChiP-PCR, gastrocnemius and plantaris muscles from weight-bearing 
and hind limb unloaded mice were removed, weighed , and immersed in 1 ml of 
the nuclear isolation buffer (NIB: 1 OmM of HEPES pH7.5, 10mM MgCI2 , 60mM 
KCI, 300mM sucrose, 0.1mM EDTA pH 8.0, 0.1% Triton X-100, 1mM OTT, 
0.15mM spermine and 0.5mM spermidine, 0.1 mM PMSF, 2j..Jg/ml aprotinin, 
2j..Jg/ml leupeptin). The muscle was finely minced using sterile scalpels and 
transferred to a 1.5 ml microcentrifuge tube. The minced muscle was crosslinked 
by adding fresh formaldehyde to a final concentration of 1% and rotating at room 
temperature (RT) for 15 minutes. Crosslinking was stopped by adding glycine to 
a final concentration of 0.125M and rotating at RT for 5 minutes. Tubes were 
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centrifuged at 1500xg for 5 minutes at 4 oc and washed twice with PBS 
containing 1x protease inhibitor cocktail [(PIC), Roche Applied Bioscience]. After 
the last spin, the supernatant was discarded and the pellet was snap frozen in 
liquid nitrogen and stored at -80°C. After thawing, each pellet was suspended in 
1.5 ml of NIB, transferred to a 14 ml round bottom tube (BD Falcon) , and 
homogenized mechanically. The homogenates were centrifuged at 180xg for 1 
minute and the supernatants saved. Pellets were re-suspended in 1.5 ml NIB 
and homogenized again to maximize the number of nuclei released from 
myofibrillar material. Homogenates from both legs of the same mouse were 
pooled and passed through a 100 IJm cell strainer (BD Falcon) by centrifugation 
at 11 OOxg for 5 minutes at 4oC to filter residual myofibrillar material from the 
nuclei. The filter process was repeated with a 40 1Jm cell strainer (BD Falcon), 
and then nuclei were pelleted by centrifugation at 11 OOxg for 5 minutes. Each 
cell strainer was then washed twice with 2 ml of ice cold PBS containing 1x PIC, 
then centrifuged to pellet any nuclei stuck in the strainer. 
The nuclei were processed for ChiP using modifications of the method 
described by Tachibana eta/ (73). Nuclei were re-suspended in sonication buffer 
with PIC. Aliquots of 350 to 400 IJI were sonicated on ice with a Sonic 
Dismembrator Model 100 (Fisher) at setting 2 for 30 seconds with one minute in 
between for 9 to 12 cycles. Nuclear debris was pelleted by spinning the 
sonicated material at maximum speed in a microfuge for 5 minutes, and the 
supernatant containing fragmented chromatin was saved for immune-
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precipitation . The extent of sonication was evaluated by removing 10 IJI 
supernatant for treatment with Pronase, RNase A, and reverse crosslinked , and 
then DNA was extracted with phenol/chloroform and precipitated with ethanol. 
DNA was size fractionated on a 1% agarose gel where approximately 90% of the 
DNA was visualized as a smear between 300 - 800 bp. Equal amounts of 
fragmented chromatin from each group, weight-bearing and hind limb unloaded, 
were diluted in IP dilution buffer (73) and pre-cleared twice using the Protein G 
conjugated magnetic beads (Dynabeads, Invitrogen) that had been blocked 
overnight with BSA and sonicated fish sperm DNA (Roche Applied Bioscience) . 
The beads were pelleted by centrifugation and the supernatant containing the 
chromatin was aliquoted: a 100 J..JI aliquot as an input sample not immune-
precipitated , and four aliquots with equal amount of the remaining supernatant 
(-700-1000 IJI each). One aliquot was incubated with lgG as a negative control 
and the other three chromatin aliquots were immunoprecipitated by incubation 
with 10 J..Jg of antibody (Santa Cruz) , directed against either p65 (SC-372X) , p50 
(SC-1190X), or Bcl3 (SC-185X) for 16 hours at 4 °C. The antibody-chromatin 
complexes were warmed to RT in a water bath and an equal volume of pre-
blocked magnetic beads was added and placed on a rotator for 15 minutes at 
RT. The tubes were then placed in a magnetic tube rack (Magnasphere 
separation stand, Promega) to allow capture of beads on the side of the tube. 
The liquid was removed and beads were washed in a succession of buffers 
according to Tachibana eta/. (73). Finally, the conjugates were eluted from the 
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beads for 30 minutes. The protein and RNA were removed from the immune-
precipitated samples and the input sample by incubation with Pronase and 
RNase A for 2 hrs at 42°C. The sample and input tubes were processed to 
reverse the crosslinking and DNA was precipitated in ethanol with glycogen as 
carrier. The DNA from ChiP was re-suspended in 30 1-11 of Tris-low EDTA buffer 
(1 OmM Tris 8.0, 0.1 mM EDTA). For PCR, 1/15th of the each DNA sample and 
1/1 DOth of each input were used as templates in a standard Platinum Taq PCR 
reaction for 32 cycles. PCR products were separated on a 10% TBE gel (Ready 
Gel , BioRad) and stained by SYBR Gold. 
NF-KB sites for PCR study were selected by the CLOVER algorithm of 
Motifviz (http://biowulf.bu.edu/MotiNizl), which uses the JASPAR database 
(http://jaspar.genereg.net/) for its binding matrices. We selected KB sites for 
ChiP that had the best score for matching the KB consensus sequence using the 
JASPAR matrix ID: MA0061.1 . Conservation between mouse and human gene 
sequences was determined by locating the KB site in the mouse genome using 
Blat and displaying the comparative sequences at that site in the University of 
California Santa Cruz gene browser (http://genome.ucsc.edu/). Primers were 
designed with Primer 3.0 from the online workpage 
(http://frodo.wi.mit.edu/primer31). The size of the PCR products containing the 
KB sites was between 190 and 400bp for all14 ChiP assays. 
For ChiP-sequencing (ChiP-seq), tissues from four legs were pooled, 
homogenized, and chromatin isolated as described above with 2 minor 
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modifications: nuclear material was subjected to sonication to yield chromatin 
fragments that were on average 250bp and no sonicated fish sperm DNA was 
used to block Protein G magnetic beads. One tenth of the enriched nuclear 
material was used in PCR for genes already shown to give positive ChiP-PCR as 
a quality control step for ChiP. The different DNA libraries isolated from the ChiP 
with Bcl-3, p50, no antibody, and non-ChiP input chromatin were labeled for high 
throughput sequencing using the lllumina ChiP-seq Library kit. An aliquot of 
each library was examined by acrylamide electrophoresis and SYBR-gold 
staining to estimate the quality by size and intensity of the product which appears 
as a smear with average size of 250bp. The libraries were sent to The 
Whitehead Institute (Cambridge, MA) where they were cleaned of adapter dimers 
using Ampure XL beads. The cleaned libraries were tested by Bioanalyzer and 
qPCR quality control was performed in order to determine how much of each 
library to use. The libraries were sequenced using Ilium ina Solexa sequencing 
on a GA II sequencer. The resulting sequences from control and unloaded 
samples were aligned to the mouse genome (mm9 version) using ELAND. The 
sequences were sent to our lab in the ELAND format. For the Bcl-3 ChiP we 
pooled two separate ChiP-seq experiments by combining .bam forms of the 
alignments. There were 40 million sequence reads in the control samples, of 
which 20.4 million were unique, and there were 52 million sequence reads in the 
unloaded samples of which 25.9 million were unique. The aligned sequences 
converted to .sam format were uploaded to the peak finder program in 
ChiPseeqer (74). These alignment files were used for all subsequent analyses. 
2.5 Gene ontology and ChiP-Array analysis 
A list of 138 genes with increased Bcl-3 binding at the promoter region 
and increased mRNA expression due to unloading were uploaded to DAVID 
Bioinformatics database (http://david.abcc.ncifcrf.gov/) for functional annotation 
analysis. Biological process ontology of the gene list was compared to that of 
gene probes on Affymetrix Mouse Gene 1.0 ST array using Functional 
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Annotation Chart module where the threshold of EASE score (a modified Fisher 
Exact P-value) was set at 0.01 and minimum gene count was 2. Biological 
process ontology terms with Benjamin FOR value< 0.05 and fold enrichment 
>1.5 were considered as enriched biological functions represented by Bcl-3 direct 
targets. These statistical cutoffs were set based on the recommendation made 
by Huang eta/. (75) . 
To identify Bcl-3 transcriptional regulation network, lists of genes with Bcl-
3 peak in the promoter region and genes with increased mRNA expression due 
to unloading (q:5 0.01 , a total of 1616 genes) were uploaded to ChiP-Array 
(http ://wanglab.hku.hk/ChiP-Array) (76). ChiP-Array combines ChiP-seq and 
gene expression data to identify Bcl-3 direct or indirect target genes; the former 
were the genes whose expression was upregulated due to unloading and 
showed a Bcl-3 binding peak in the promoter region, whereas the latter were the 
genes that showed increased mRNA expression but lacked a Bcl-3 peak in the 
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promoter region. Transcription factor binding sites predicted by UniPROBE, 
JASPAR and UCSC databases in -8kb to +2kb promoter region of the Bcl-3 
indirect target genes were identified and searched for the putatively enriched 
transcription factors, which were also directly regulated by Bcl-3. The 
hierarchical regulation of Bcl-3 for its direct target genes or indirect target genes 
through putatively enriched transcription factors were displayed graphically by 
ChiP-Array output. 
2.6 Reporter construct and site directed mutagenesis 
The mouse MuRF1 promoter luciferase plasmid which contains 4.4kb of 
the 5' upstream MuRF1 promoter region was a gift of S. Shoelson (36). Whole 
Genome RVista algorithm (http://genome.lbl.gov/vista/citeus.shtml) (77) was 
used to identify putative transcription factor binding sites conserved between 
mouse and human genomes. Within the 4.4kb MuRF1 promoter region, there 
were three conserved putative NFKB binding sites located at 3.1, 4.1 and 4.2kb 
upstream of mouse MuRF1 transcription start site and four conserved putative 
FoxO binding sites located at 3kb, 2.5kb, 185bp, and 24bp upstream of the 
MuRF1 transcription start site. The 5' MuRF1-Iuc deletion construct (5 '~MuRF1) 
was created by cutting the 4.4kb MuRF1 -Iuc plasmid with Nhel and Smal, and 
ligating the blunt ends to remove the 5' 2.1 kb of MuRF1 promoter sequence. 
This produced a 2.3kb MuRF1 promoter reporter (5'~MuRF1) lacking the 3 
putative NF-KB sites. Also with the 4.4kb MuRF1 promoter reporter, site-directed 
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mutagenesis was performed to mutate the individual predicted NF-KB sites using 
PCR. The mutated primers were designed using the QuikChange Primer Design 
Program (Agilent, Santa Clara) then made by Invitrogen (Carlsbad, CA) . The 
target sequences are listed blow with the NF-KB site underlined and mutated 
nucleotides capitalized: KB1 5'-caa act etc agg ttt ctg aaa agt GAG ttt tct agt gac 
aat ccc aaa gag-3', KB2 5'- ccc aaa gag cac aga ctt aCT Caa gtt cca gcg eta cca 
g-3', KB3 5'- ccg ccc atg tgg gaa ctt GAG cat etc ace ctt tga ctt-3'. An aiiKB mut 
MuRF1 construct that contained 3 mutated NF-KB sites was made by 
sequentially mutating the NF-KB sites in (wild-type) MuRF1-Iuc using the primers 
described above. Similarly, an aiiFoxO mut MuRF1 construct, which lacks all 4 
FoxO sites, was made by sequentially mutating the FoxO sites in (wild-type) 
MuRF1-Iuc using the primers shown below: FBE1 5'-cca gtg tgg ctg agg aag tea 
CcC gga age tgt ga-3', FBE2 5'-ccg aaa tea cca tgc cct ttg GtG caa aga cct cct tct 
ata atc-3', FBE3 5'-tga aca gtc tgt tct tgG tGa ega ccc cca egg cag-3', FBE4 5'-
tga cag agg tgc age tat CaC tat cag agg ggc etc ag-3'. A reaction was performed 
by mixing 1 OOng of each phosphorylated primer, 1 OOng MuRF1-Iuc, 1.25U 
PfuUitra High-fidelity DNA polymerase (Agilent), and 20U Taq DNA ligase (New 
England Biolabs, Ipswich, MA) and then the reaction was performed in a thermal 
cycler set as follows: 95°C for 2min (denature) , 30 cycles of 95°C for 50sec, 60°C 
for 50sec, and 68°C for 5min, and followed by a final incubation at 68°C for 5min 
(extension) . After Dpnl treatment, amplified PCR products were transformed into 
XL 1 0-Gold Ultracompetent bacteria (Agilent) according to manufacturer's 
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instructions. The sequences of wild-type and mutated MuRF1-Iuc reporters were 
verified by Genewiz sequencing services (South Plainfield , NJ). 
2. 7 In vivo reporter plasmid electrotransfer and reporter assays 
In vivo reporter plasmid electrotransfer was performed by injecting 401-Jg of 
wild-type or mutant MuRF1-promoter reporters into rat soleus muscle followed by 
5 pulses of electroporation directly on soleus muscles at 1 OOV/cm, 20ms, 1Hz, 
with 200ms interpulse interval as previously described (5). Twenty four hours 
after reporter electrotransfer, rats were randomly assigned to either the weight-
bearing group or the HU group. The HU group of rats had their hind limbs 
removed from weight-bearing for 6 days by elastic tail cast as described 
previously (5). Soleus muscles transfected with reporter plasmid were 
homogenized in 1 ml passive lysis buffer (Promega, Madison, WI). 
Homogenates were centrifuged at 5,500g at 4°C for 20min. Supernatant was 
collected , diluted 1:20, and mixed with 1 001-JIIuciferase assay reagents 
(Promega). Luciferase activity was measured by a TD-20/20 illuminometer 
(Turner Designs Inc), which reflected total muscle luciferase activity. 
2.8 Statistical analysis 
For RT-qPCR and luciferase activity, a two-tailed independent t-test was 
performed to determine statistical significance between WB and HU groups. A P 
value less than 0.05 was considered statistically significant. 
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Chapter 3 Identification of Bcl-3 and p50 target genes in disuse atrophy 
using expression arrays and knock-out mice 
3.1 Introduction 
Nuclear factor kappa B (NF-KB) signaling is a key signaling pathway in 
adult skeletal muscle atrophy. Unloading induced NF-KB activation in skeletal 
muscle occurred as early as 3 days after unloading and was sustained for at 
least 10 days (4,56). Of the five mammalian Rei transcription factors, p50 and c-
rel showed increased nuclear localization in unloaded muscles compared to 
weight-bearing muscles (4). Nuclear levels of Bcl-3, an IKB family member that 
acts as a NF-KB transcriptional co-activator, are also markedly increased with 
unloading (4). Gel supershift results also suggested the involvement of p50, c-
rel, and Bcl-3 in NF-KB activation during unloading atrophy (4). Strikingly, 
experiments using mice null for the nfkb1 (encodes for p1 05 which can be 
proteolytically processed to p50), e-re/, or bc/3 gene showed that p50 and Bcl-3, 
but not c-rel, were required for skeletal muscle atrophy, NF-KB activation, and the 
slow-to-fast fiber type transition with unloading (56). 
Since nfkbr'- or bc/3_,_ mice showed that p50 and Bcl-3 are required for 
unloading atrophy, we sought to identify the downstream target genes of p50 and 
Bcl-3 that drive the atrophy process. This was accomplished by comparing the 
global mRNA expression profiles of muscles from wild-type mice to that of 
muscles from p50 or Bcl-3 knockout mice in weight-bearing and unloading 
conditions. Genes that were upregulated in the unloaded muscles from wild-type 
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mice but not upregul<;~ted in the unloaded muscles from nfkbr'- or bc/3_,_ mice 
were considered p50 or Bcl-3 target genes during disuse atrophy. The reason 
for focusing on upregulated genes is that previous work showed a marked 
upregulation of NF-KB dependent reporter in atrophying muscles. Direct binding 
of p50 and Bcl-3 to the KB sites in the promoter of 14 genes, which have been 
shown to have known or inferred functions in muscle atrophy were studied in 
further detail by ChiP-PCR. 
3.2 Results 
3.2.1 Muscle Atrophy 
There was an 18% decrease in combined muscle mass of gastrocnemius 
and plantaris for wild-type 6-day hind limb unloaded mice (wet weight normalized 
to body weight), but there were little or no loss in muscle mass for the same 
muscles from bc/3_,_ or nfkbr'- mice (Table 3.1 ). This is consistent with the 
atrophy we reported previously in plantaris muscles due to 10 days of unloading 
in wild-type, bc/3-'-, and nfkbr'- mice (56). 
3.2.2 Microarray analysis of muscle from wild-type and knockout mice to identify 
direct or indirect targets of Bcl-3 and p50 in disuse atrophy 
We identified 240 genes whose expression increased in atrophied 
gastrocnemius and plantaris muscles from wild-type mice due to unloading but 
not in bc/3 _,_mice. Because muscles from bc/3 _,_mice were resistant to disuse 
atrophy, these 240 genes were thus considered as direct or indirect target genes 
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ofBcl-3 in disuse atrophy. The complete list of these 240 Bcl-3 targets is shown 
in Appendix 1. To understand the functions of these Bcl-3 target genes, the 
genes were categorized based on their molecular function and biological 
processes assigned by the Gene Ontology Consortium as shown in Table 3.2. 
Most of the Bcl-3 target genes are involved in signaling (13%), metabolism 
(1 0%), translation (9%), protein degradation (9%), transcription (8%), and 
transport (8%). 
The same approach was used to identify direct or indirect targets of p50 
using nfkbr'- mice. We identified a list of 185 genes that were direct or indirect 
targets of p50 in disuse atrophy, which is shown in Appendix 1. Most of the p50 
target genes are involved in signaling (15%), translation (1 0%), metabolism 
(1 0%), protein degradation (9%), transcription (8%), and transport (6%). 
Comparing the two target gene lists, we found that all p50 gene targets were also 
Bcl-3 gene targets in disuse muscle atrophy. 
3.2.3 Quantitative real-time PCR of selected atrophy genes 
From the microarray data, we identified 25 Bcl-3 and/or p50 target genes 
encoding proteins with known or inferred function in muscle atrophy. Fourteen of 
these genes were selected for quantitative real-time PCR (qPCR) measurement 
to validate microarray results; 7 genes encode proteins in ubiquitin-proteasome 
mediated protein degradation (Figure 3.1 A-G), 3 genes encode transcription 
factors (Figure 3.1 1-K), and others genes are involved in lysosome-mediated 
protein degradation (ctsf), an inhibitor of protein synthesis (eif4ebp1), a 
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chemokine (cxc/10) and a cytokine receptor (tnfrsf12a). In the 14 atrophy genes 
studied, all of them showed a significant >1.5-fold upregulation in mRNA 
expression in the unloaded muscles compared to weight-bearing muscles from 
the wild type mice (Figure 3.1 ). Unloading induced either no increase, or a 
significantly less increase in mRNA expression of all 14 genes in bc/3_,_ and 
nfkbr'- mice except for Fbxo9 and Fox03 (Figure 3.1 A-C, E-H, J-M). Thus, 12 
of these 14 gene studied were confirmed to be direct or indirect targets of Bcl-3 
and p50 by qPCR. In the case for Fbxo9 and Fox03 (Figure 3.1 D, 1), unloading 
induced a significant upregulation in their mRNA expressions in muscles from the 
wild type and nfkbr'- mice, but not from the bc/3_,_ mice. These two genes were 
therefore confirmed as targets of Bcl-3 in disuse atrophy, but not p50 target 
genes. GAPDH did not change with unloading in wild-type or mutant mice and 
so it was used for normalization of all the mRNAs measured by qPCR (Figure 
3.1 0). 
3.2.4 Chromatin immunoprecipitation (ChiP) of selected Bcl-3 and P50 target 
genes 
To assess whether Bcl-3 and p50 bind to NF-KB binding sites for the 14 
qPCR-confirmed Bcl-3 and p50 target genes in disuse atrophy, we performed 
ChiP assays using gastrocnemius and plantaris muscles from wild-type mice with 
or without unloading. To identify putative KB binding sites in each gene to be 
studied, we used CLOVER (78) to search for over-represented KB sites in the 
genomic sequence from 1 Okb upstream of transcription start site (TSS) of each 
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gene to 1 Okb downstream of its polyadenylation signal. The identified putative 
KB sites were studied for sequence conservation between mouse and human by 
the BLAT alignment tool in UCSC Genome Browser (http://genome.ucsc.edul). 
Of the 14 genes studied, 11 had conserved KB sites. The other 3 genes, fbxo9, 
psmg4 and eif4ebp1, contained non-conserved KB sites. The location of KB sites 
relatively to the TSS of these 14 genes studied is listed in Table 3.3. 
Increased Bcl-3 binding was observed in 7 of the 14 genes studied due to 
unloading. These genes are atrogin1, murf1, ubc, ctsl, runx1, tnfrsf12a, and 
cxc/10 (Figure 3.2 A-G) . These seven genes were thus considered as direct Bcl-
3 binding targets in unloading atrophy. Of these 7 genes, chromatin isolated 
from weight-bearing and unloading muscle showed p50 binding to the putative 
KB site where Bcl-3 bound to during unloading. Unloading induced p50 binding 
was either increased (Murf1, runx1, and cxc/10), or showed no change (atrogin-
1, ubc, ctsl, tnfrsf12a). The increased Bcl-3 binding to the putative KB site where 
p50 was also bound suggests increased formation of Bcl-3/ p50 complexes 
regulates atrogin-1, Murf1, ubc, ctsl, runx1, tnfrsf12a, cxc/10 during disuse 
atrophy. However, there were no significant changes in Bcl-3 and p50 binding to 
the proteasome subunit genes (i.e. psmc4, psmg4, and psma6 in Figure 3.2 H-
J), fbxo9, ankrd1, foxo3, and eif4ebp1 (Figure 3.2 K-N). Thus, none of these 7 
genes appears to be direct p50 or Bcl-3 binding targets in unloading atrophy. 
For comparison, we also measured binding of p65 with unloading, the 
prototypical NF-KB transcription factor family member. Of the 7 ChiP-PCR 
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identified Bcl-3 and p50 direct binding targets , there were marked decreases in 
p65 binding for 4 genes, atrogin1, murf1, ctsl, and cxc/10 (Figure 3.2 A, B, D, G). 
No detectable p65 binding was seen in control or unloaded muscle for ubc or 
runx1 (Figure 3.2 C, E). A moderate increase in p65 binding was observed only 
in one gene, tnfrsf12a (Figure 3.2 F). The fact that most of the genes studied 
showed a lack of p65 binding to KB sites in promoter regions due to unloading 
supports our earlier observation that p65 is not a major player in disuse muscle 
atrophy (56). 
3.3 Discussion 
Identification of genes that are p50 and Bcl-3 targets is a first step to 
understand the molecular basis of the atrophy phenotype. This work represents 
the first study using a global gene expression approach to identify genes required 
for producing atrophy due to muscle unloading. We identified 185 target genes 
that were direct or indirect targets of p50 and 240 target genes of Bcl-3 in disuse 
atrophy. Functional analysis of these two target gene lists based on their 
function in the muscle showed that most genes were involved in signaling , 
metabolism, protein degradation, translational or transcriptional regulations , 
which are consistent with the changes seen in other studies to describe muscle 
atrophy phenotypes (35). Since we were interested in finding genes regulated by 
p50 or Bcl-3 which are required for producing atrophy, 14 microarray-identified 
target genes were studied in further detail to distinguish direct from indirect 
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targets. These genes are involved in protein degradation (fbxo32, MuRF1, ubc, 
ctsl, fbxo9, and 3 proteasomal subunits), transcription regulation (runx1 , ankrd1 
and foxo3) or signaling proteins (tnfrsf12a, cxc/10 and eif4ebp1) . qPCR results 
confirmed that all but two (fbxo9 and foxo3) of the 14 genes were direct or 
indirect targets of p50 and Bcl-3 where upregulated mRNA due to unloading in 
wild-type mice was either abolished or significantly attenuated compared to 
weight-bearing control muscles in either gene knockout mouse. 
Our microarray study demonstrated that all of the p50 target genes in 
unloading atrophy were also recognized as Bcl-3 targets. This significant overlap 
between the two target gene lists (77%) and the fact that upregulated NF-KB 
activity due to unloading in wild type mice was abolished in nfkbr1- and bc/3_1_ 
mice (56) led us to propose that p50 and Bcl-3 may act in a complex to 
transactivate genes essential for atrophy processes via binding to NF-KB sites. 
In several non-muscle cell types, the Bcl-3/p50 homodimer complex have been 
shown to transactivate gene expressions such as bc/2 (79) , egfr (67) , or iNOS 
(69) . However, this is the fi rst study to examine both Bcl-3 and p50 target genes 
at a whole transcript level. On the other hand, our microarray identified 60 genes 
that were Bcl-3 target genes, but no p50 target genes. This suggested that Bcl-3 
may activate genes independent of p50. Indeed , Bcl-3 has been shown to 
complex with another NF-KB transcription factor, p52, in cell lines from myeloma 
(46) , breast cancer (49) and human CMV infected monocyte-derived 
marcrophages (80). Binding of Bcl-3/p52 homodimer complex to NF-KB sites is 
required for activating genes such as cyclin 01 (81) and P-selectin (82). Also , 
Bcl-3 has also been shown to regulate gene expressions in a non-NF-KB 
dependent manner by directly binding to proteins such as c-Jun (54) and 
estrogen-related receptor alpha (53). Thus it may be interesting to determine if 
other Bcl-3 binding partners besides p50 are required for unloading atrophy. 
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ChiP-PCR results which showed increased Bcl-3 binding to KB sites in 
promoters of 7 genes (out of the 14 atrophy-related genes studied) in unloaded 
muscles compared to weight-bearing muscles. Interestingly, all genes studied 
showed p50 binding in weight-bearing muscle, and with unloading, p50 binding 
either did not change or increased in the 7 genes where Bcl-3 binding was 
increased. We interpret these data to indicate that Bcl-3 transactivates atrophy 
related genes by binding to p50 in unloading atrophy. Here we identified fbxo32, 
MuRF1 , ubc, ctsl, runx1, tnfrsf12a, and cxc/1 0 as direct target genes of Bcl-3 and 
p50 in unloading atrophy. However we cannot rule out that there may be other 
factors involved. For instance, FoxO was also shown to be required for disuse 
atrophy (62) and the target genes are under study (unpublished observations) . 
It is interesting that all three proteasomal genes chosen for further study 
were indirect rather than direct KB target genes because there was no change in 
p65, p50, or Bcl-3 binding with unloading. It is possible that upregulated 
proteasomal subunit expression due to unloading is regulated by transcription 
factors other than NF-KB, which are downstream of p50 and Bcl-3 targets. · It 
should also be noted that there are several limitations for ChiP-PCR; for 
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instance, since we only examined protein binding to putative KB sites within 1 Okb 
upstream of the transcription start site of the gene of interest, it is possible that 
the regulatory sequence of a gene is located outside of the region we examined . 
In addition, ChiP-PCR is more of a qualitative than a quantitative approach and 
DNA-protein binding does not infer gene transactivation. The lack of increased 
p65 binding to putative KB sites in all but one of the 14 genes studied by ChiP is 
consistent with our previous finding which suggested the lack of primary 
involvement of p65 in unloading atrophy (4 ,56). This is in contrast with some 
types of muscle atrophy associated with an activated immune response where 
p65 may play a role in regulating atrophy genes via binding to KB sites 
(36,83,84). 
To date, we do not know the upstream signals that activate p50 and Bcl-3 
in response to unloading. Previous studies showed that Bcl-3 could be 
upregulated by a number of cytokines such as TN F-a (85), IL-4 (86), or IL-6 (87) . 
However, our microarray data did not show upregulation of these cytokines nor 
was there an upregulation of other immune response genes (e.g., acute phase 
response) during unloading. Therefore, it is unlikely that Bcl-3 and p50 are 
activated by cytokines during unloading. Another study reported that oxidative 
stress induced by a glutathione inhibitor, buthionine sulfoximine, facilitates Bcl-3 
binding to p50 homodimers and promotes their nuclear translocation (79). Since 
oxidative stress is activated in disuse atrophy and known to regulate signaling 
pathways important for muscle protein synthesis and degradation (63), it is 
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possible that increased oxidative stress due to unloading promotes Bcl-3 binding 
to p50 homodimers to upregulate atrophy genes. Additionally, Bcl-3 is known to 
be regulated by post-transcriptional mechanisms such as phosphorylation (52) 
and ubiquitination (88) . Depending on the co-activators or transcription factors 
binding Bcl-3 the target genes can be either activated or repressed (88) . From 
these studies we have created a list of NF-KB regulated genes in unloading 
atrophy, and , we determined that 7 of the 14 genes studied in detail using ChiP 
are direct targets of p50 and Bcl-3. These data in combination with the lack of 
increases in p65 binding at KB sites in 13 of the 14 upregulated genes studied , 
suggests a primary role for p50 and Bcl-3 rather than the canonical NF-KB 
transcription factor, p65. There are likely other transcription factors required for 
unloading atrophy; gene regulation is created by interactions of several factors in 
complexes or in separate sites on the promoter and regulatory regions. 
However, it is clear that loss of either of these proteins in the knockout mice 
eliminates or profoundly reduces the atrophy produced by unloading and 
therefore our candidate list not only outlines the scope of genes whose products 
create muscle wasting, but it also indicates the important genomic sites of 
regulation with which we will be able to understand unloading atrophy at the 
molecular genetic level. 
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Table 3.1 Muscle weights for weight-bearing and hind limb unloaded mice 
Muscle mass/ body mass (mg/g) Percentage of 
Mice strain Weight-bearing Hind limb unloaded muscle atrophy 
WT 5.22 ± 0.11 4.30 ± 0.16 18%* 
Nfkbr'- 5.50 ± 0.04 5.13 ± 0.08 6.7%* 
Bcl-3+ 4.86 ± 0.07 4.55 ± 0.16 n.s. 
Muscle IS gastrocnemius plus plantans. Values are mean ± SEM. * 1nd1cates different 
from WB value (P<0.05). n.s. indicates no statistical difference from WB value. 
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Table 3.2 Functional categories of target genes for Bcl-3 and p50 from 
microarray analysis 
Bcl3 targets pSO targets 
Gene# Percentage Gene# Percentage 
Signaling 31 12.92% 28 15.14% 
Metabolism 24 10.00% 18 9.73% 
Translation 22 9.17% 19 10.27% 
Protein degradation 21 8.75% 17 9.19% 
Transcription 21 8.75% 16 8.65% 
Transport 19 7.92% 12 6.49% 
Non-annotated or 
RIKEN eDNA 14 5.83% 9 4.86% 
Mise: immune/ 
proliferation/ ECM 13 5.42% 11 5.95% 
RNA processing 12 5.00% 9 4.86% 
Cytoskeleton 11 4.58% 9 4.86% 
Chromatin modification 10 4.17% 7 3.78% 
Cell adhesion 7 2.92% 6 3.24% 
Structure 7 2.92% 5 2.70% 
Development 7 2.92% 4 2.16% 
Cell cycle 6 2.50% 4 .. 2.16% 
Binding 5 2.08% 4 2.16% 
Anti-oxidant 4 1.67% 3 1.62% 
Muscle contraction 3 1.25% 3 1.62% 
Stress 3 1.25% 1 0.54% 
.. Gene# denotes the number of Bcl-3 or p50 target genes 1dent1f1ed for each funct1onal 
category. Percentage represents the ratio of genes in a specific functional category 
relative to total number of target genes (240 and 185 for Bcl-3 and p50, respectively) . 
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Table 3.3 Location of putative KB sites relative to the TSS of the 14 genes 
studied by ChiP assay 
Gene name Official Symbol Distance from TSS 
F-box protein 32 Atrogin1 (Fbxo32) 
-550 bp 
tripartite motif-containing 63 MuRF1 (Trim63) +4.8 kb (intron 3) 
Ubiquitin C Ubc -1.4 kb 
Cathepsin L Ctsl -5.5 kb 
Runt-related transcription factor 1 Runx1 -1 .7 kb 
Tumor necrosis factor receptor superfamily, Tnfrsf12a -5.7 kb 
member 12A 
Chemokine (C-X-C motif) ligand 10 Cxcl10 -157 bp 
Proteasome (prosome, macropain) 26S Psmc4 -1.9 kb 
subunit, ATPase, 4 
Proteasome (prosome, macropain) Psmg4 -2 .7 kb 
assembly chaperone 4 
Proteasome (prosome, macropain) subunit, Psma6 -3.2 kb 
alpha type, 6 
F-box protein 9 Fbxo9 -1 .2 kb 
Ankyrin repeat domain 1 (cardiac muscle) Ankrd1 -2.3 kb 
Forkhead box 03 Foxo3 -2.0 kb 
Eukaryotic translation initiation factor 4E Eif4ebp1 -2.7 kb 
binding protein 1 
Distance from TSS denotes the locat1on of the Identified NF-KB site relative to the 
transcriptional start site (TSS) of the associated gene. 
A 
3 
c: 
.2a;-
~ !? 2 ~ ... 
.a. .c: 
!~1 z 0 . 
a:!!::. 
E 
E 
2.0 
c: 
.Q G) 1.5 
~ Cl 
., c: 
~ "' ~-5 1.0 ;:r. 
., 
<(3! 
z.£ a:~ 0.5 
E 
M 
c: 2 
.Sa;-
"' Cl ., c: 
~ "' 0..<: 
>< () 
., 32 1 
< 0 Zu. a:~ 
E 
MuRF1 
•t 
Psma6 
,I 
Fox03 
Eif4ebp1 
B 
6 
F 
c: 1.5 
.2-
., ., 
., Cl 
a.~ 1.0 ~-5 
<(:2 
z 0 a:!!::. 0.5 
E 
J 
4 
N 
Atrogin-1 
Psmc4 
•t 
Runx1 
Cxcl10 
c 
-~- 4 ., ., 
"' Cl ~ ~ 3 O...c: 
>< () 
.,322 
<( 0 
Zu. a:~ 
E 1 
G 
c: 1.5 
-~G) 
<I) Ol 
a.~ 1.0 
~0 
.i;32 
z 0 a:!!::. 0.5 
E 
K 
0 
1: 
-~ G) 
"' Cl Cl) c: 
2 
~ "' ~-5 1 
CI)"C 
<(-
zO 
a:!!::. 
E 
Ubc 
•t 
Psmg4 
Ankrd1. 
Gapdh 
D 
c: 1.5 
.Q-
"' Cl) 
"' Cl Cl) c li ~ 1.0 
)( t.l 
CI)"C 
<-z 0 
a:!!::. 0. 
E 
H 
L 
Fbxo9 
Ctsl 
Tnfrsf12a 
c Weight-bearing 
1!!!1 Hind limb unloading 
Figure 3.1 Expression changes of selected microarray-identified Bcl-3 and P50 
target genes in disuse atrophy. Q-PCR was performed on muscles from wild-type 
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ryvT) , bc/3 -I- and nfkb1 -I- mice with or without 6 days of unloading. Gene expression 
was measured for: A) MuRF1 (Trim63), B) Atrogin-1 (Fbxo32) , C) Ubc, D) Fbxo9, E) 
Psma6, F) Psmc4, G) Psmg4, H) Ctsl , I) Foxo3, J) Runx1 , K) Ankrd1 (Carp), L) 
Tnfrsf12a, M) Eif4ebp1 , and N) Cxcl10 (IP-10) . All14 genes measured confirmed a 
significant mRNA upregulation due to 6 days unloading (HU) compared to weight-
bearing (WB) in muscles of wild-type ryvT) mice. Gene expression due to unloading in 
knockout mice (Bc/3 -I- or Nfkb -I-) was either not different from weight-bearing or it had a 
significantly less increase for all cases except Fbxo9 and Foxo3 in nfkb1 -I- mice. 
GAPDH expression 0) was measured as a loading control which showed no increase 
with unloading in all groups. *significantly different from weight-bearing value (P<0.05), 
tsignificantly different from wild-type unloaded value (P<0.05). 
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Figure 3.2 ChiP-PCR of Bcl-3, p50, and p65 binding to genes from Figure 3.1. 
ChiP assay was performed using weight-bearing (WB) and unloaded (HU) 
gastrocnemius/plantaris muscles from wild-type mice. For each gene shown, binding of 
Bcl-3, p50 and p65 protein to a 600-800bp DNA sequence flanking a putative NF-KB 
binding site was assayed. There was an increase in Bcl-3 protein binding to 7 of the 14 
genes studied: A) Fbxo32, B) Trim63, C) Ubc, D) Cts/, E) Runx1, F) Tnfrsf12a, and G) 
Cxc/10. There were also increases in p50 (B, E, G) and decreases in p65 (A, B, D, G) 
in these 7 genes. None of the proteasomal subunit genes showed changes in Bcl-3, 
p50, or p65 binding, Psmc4., Psmg4, or Psma6 (H-J). Fbxo9, Ankrd1 , Foxo3, and 
Eif4ebp1 (K-N) genes also did not show changes in the binding of these proteins to kB 
sites. For each gene, ChiP assays were repeated using different samples from WB and 
HU groups. The PCR product size for all14 ChiP assays performed was between 190 
to 400bp. 
Chapter 4 Genome-wide identification of Bcl-3 target genes in disuse 
atrophy by ChiP-sequencing and whole transcript microarray analyses 
4.1 Introduction 
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Skeletal muscle atrophy is the result of a metabolic shift that increases the 
rate of proteolysis and/or decreases the rate protein synthesis in the cells that 
make up muscle. The initiating triggers for this shift are varied, but fall into two 
main categories: the result of a disease or pathology such as cancer, diabetes, 
HIV, major body burns, and sepsis , or the loss of muscle as a result of 
immobilization, bed rest, diaphragm breathing assistance, or decreases in gravity 
as in space travel (1 ,89-91 ). Since the triggers of atrophy differ it might be 
expected that there are differences in the cellular processes that control disuse-
and disease-induced muscle atrophy (92,93) . 
Studies on the signaling pathways activated by muscle disuse due to the 
removal of weight-bearing (i.e., unloading) showed that nuclear factor-kappaS 
(NF-KB) activity was increased early and continuously (4,56,66). The NF- KB 
transcription factors showing increased localization to the muscle cell nuclei were 
p50 and Bcl-3, but not p65 (4). Viable knockouts of p50 and Bcl-3 made 
possible the finding that the elimination of either gene alone would block muscle 
atrophy due to unloading (56). To identify the genes regulated by p50 or Bcl..;3 
that produce the atrophied phenotype, global gene expression analysis was used 
to compare wild-type and the two knockout strains of mice in response to 
unloading (28). The genes upregulated in wild-type mice that were not 
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upregulated in knockout mice due to unloading were from several muscle atrophy 
gene functional groups including proteolysis. However, this analysis cannot 
distinguish direct vs. indirect target genes. 
In the present study, we focused on finding the direct target genes of NF-
KB transcription factors during muscle unloading We used chromatin 
immunoprecipitation followed by next generation sequencing (ChiP-seq), a 
recently developed method in which the location of particular transcription factors 
is mapped to the whole genome during physiological or pathological changes. 
The active molecules of NF-KB consist of a protein complex with two or more 
subunits. In the case of p50 and Bcl-3 the active molecule is thought to consist 
of a homodimer of p50, which contains the DNA recognition and binding activity, 
and a bound molecule of Bcl-3 which has two transactivation domains for the 
induction of gene expression (46,47). Using antibodies for p50 and Bcl-3 to 
immunoprecipitate the muscle chromatin followed by high-throughput sequencing 
and high-resolution genome mapping, we identified the genes that are being 
bound by these NF-KB transcription factors in unloaded muscle. Gene ontology 
analysis showed that Bcl-3 is responsible for targeting proteolytic genes and the 
genes of glycolytic metabolism in muscle disuse, including those associated with 
type II diabetes. We have identified for the first time, a gene target network 
regulated by a transcription factor (Bcl-3) that is required for skeletal muscle 
atrophy. 
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4.2 Results 
4.2.1 Characterization of Bcl-3 binding peaks in disuse atrophy 
Since transcriptional activation of the p50-Bcl-3 complex requires Bcl-3 
binding to the p50 homodimers (46) , we sought to identify target genes bound by 
Bcl-3 during disuse atrophy at the genome-wide level. Chromatin isolated from 
weight-bearing and 5-day unloaded gastrocnemius and plantaris muscles from 
wild type mice were immunoprecipitated by Bcl-3 antiserum and sequenced for 
Bcl-3 binding . ChiP-seq yielded 40 million sequence reads in the weight-bearing 
samples, of which 20.4 million were unique, and there were 52 million sequence 
reads in the unloaded samples of which 25.9 million were unique. Using a low 
stringency peak height cutoff in ChiPseeqer (74) peak detection algorithm, we 
identified 49,000 Bcl-3 peaks. Bcl-3 peaks were defined as DNA sequences with 
significantly increased Bcl-3 binding (sequence reads) in unloaded muscles 
compared to weight-bearing. These unloading-induced 49,000 Bcl-3 peaks were 
evenly distributed across the mouse genome as shown in Figure 4.1. Using the 
Nebula algorithm (94,95) , distribution of the Bcl-3 peaks were compared to 
random peaks found from the input fraction of chromatin and is plotted in Figure 
4.2. The majority of the Bcl-3 peaks were distributed within the -500 to +500bp 
region relative to transcription start site (TSS) of associated genes whereas 
peaks of the input fraction were evenly distributed regardless of their distance 
from TSS. This showed that the Bcl-3 ChiP had succeeded in enriching many 
Bcl-3 binding peaks near the activation sites of transcription across the genome. 
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For further analysis, we used a more stringent peak height cutoff in the 
ChiPseeqer peak detection algorithm to find peaks showing at least a 2-fold 
increase in Bcl-3 binding in unloaded muscle over weight-bearing. This allowed 
us to identify 2,817 unloading-induced Bcl-3 peaks in our ChiP-seq data. To 
understand the evolutionary conservation of the identified Bcl-3 peaks, 
PhastCons analysis was performed using the Cistrome/Galaxy program (95). 
The conservation plot (Figure 4.3) showed that unloading-induced Bcl-3 peaks 
showed greater phylogenetic conservation at the center of the peaks than their 
flanking regions. The evolutionarily conserved Bcl-3 binding sites could be 
functionally important. We next annotated the distribution of these 2,817 Bcl-3 
peaks according to gene parts (e.g., promoter, exons, introns). As shown in 
Figure 4.4, Bcl-3 peaks were preferentially located in the promoters of the genes 
(from -4 to +2kb relative to the TSS) compared to the random peaks found in the 
input fraction of chromatin from unloaded muscle (30% vs. 8.2%). We then 
focused on genes associated with one or more Bcl-3 peaks in the promoter 
regions, which could be annotated to 938 genes. 
4.2.2 Gene ontology terms over-represented by Bcl-3 peak in disuse muscle 
atrophy 
To understand the functions of the genes with a Bcl-3 peak in the 
promoter region, we used the iPAGE algorithm in ChiPseeqer to identify gene 
ontology (GO) terms over-represented by the 938 genes. There were 23 GO 
terms enriched by genes with Bcl-3 peaks in promoters in disuse atrophy (Figure 
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4.5) compared to random distribution. Most of the enriched GO terms were 
associated with protein catabolism (11 GO terms) , development (7 GO terms), 
glucose metabolism (4 GO terms) or phosphatases (1 GO term). The most 
abundant group with 14 genes in 11 GO pathways was for protein catabolism . 
The genes are ones that function in several aspects of catabolism in muscle 
including several E3 ligases of the ubiquitin proteasome pathway, and 
importantly, two genes that contribute to the cell catabolism driven by the N-end 
rule. Those genes are Ubr1/E3a, theN-end recognin E3 ligase, and Ate1, the 
arginyltransferase responsible for modifying several amino acid amino termini for 
Ubr1 recognition. The sequence alignments and locations for the peaks for 
these two genes have been visualized by use of the Integrative Genomics Viewer 
(IGV) , (http://www.broadinstitute.org/igv/) and are shown in Figure 4.6. For both 
genes, a Bcl-3 peak due to unloading was identified at an evolutionary conserved 
region among mammalian sequences close to the TSS and was in close 
proximity to a JASPAR matrices defined NF-KB site. In addition , data for ChiP-
seq with p50 antibodies showed p50 binding at or near the peak sites of Bcl-3 
binding (data not shown). Another E3 ligase found was Trim63/MuRF1, a 
muscle-specific protein thought to target heavy myosin chains during atrophy 
(31 ,96). Our ChiPseq data identified a Bcl-3 peak at one of the in silica-identified 
NF-KB sites located 3.1 kb upstream of MuRF1 transcription start site (TSS). The 
alignments for the Bcl-3 binding site in the MuRF1 promoter are shown in Figure 
4.7 . Data for ChiP-seq with p50 antibodies are also presented, showing a 
putative p50 binding site and a p50 peak identified by ChiPseeqer close to the 
peak of Bcl-3 binding . 
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Also found in the GO pathways and shown in Table 4.1 are genes that 
function in the reduction of reactive oxygen species, including SOD1 , and several 
phosphatases. The other GO terms having genes represented are those 
involved in regulating myogenesis, particularly in the Wnt pathway, and those in 
glucose metabolism, including glycogen phosphorylase (Pygm) and 
phosphofructo-kinase (Pfkl), genes that liberate glucose and control its glycolytic 
metabolism respectively. Several of the genes, especially the E3 ligases found 
as Bcl-3 targets by ChiP-seq were subject to qPCR to verify gene activation 
during unloading and these data are shown in Table 4.2 . 
. 4.2.3 Direct and indirect targets of Bcl-3 in disuse atrophy 
Because we were interested in identifying upregulated Bcl-3 direct targets 
in disuse atrophy, global gene expression changes of gastrocnemius and 
plantaris muscles from wild type mice due to 5 days of hind limb unloading were 
measured by Affymetrix Mouse Gene 1.0 ST arrays. Approximately 16% of 
genes studied were differentially expressed in the unloaded muscles compared 
to weight-bearing muscles using a q-value cutoff of 0.01 (3430 out of 21212 
genes). Among the 938 genes with Bcl-3 peaks in the promoter region , 138 
genes showed upregulated mRNA expression due to unloading whereas 95 
genes were downregulated. Because we hypothesized that Bcl-3 and p50 work 
in a complex to transactivate genes essential for inducing muscle atrophy, these 
138 genes were considered as Bcl-3 direct targets in disuse atrophy. To 
understand the functional categories over-represented by the identified Bcl-3 
direct targets, the functional annotation tool in DAVID database was used to 
identify enriched GO terms. As shown in Table 4.3, there were 41 GO terms 
over-represented by the Bcl-3 direct targets in disuse atrophy. Consistent with 
the iPAGE analysis , most of the Bcl-3 target genes were associated with 
metabolism (24 GO terms) , transcription (5 GO terms), biosynthetic process (9 
GO terms), chromatin modification or reorganization (3 GO terms) functions. 
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To further understand the hierarchical regulations of direct and indirect 
target genes by Bcl-3 during unloading , genes lists showing increased Bcl-3 peak 
in promoter regions by ChiPseq were overlaid with those with upregulated mRNA 
expression due to unloading by microarray using ChiP-Array 
(http://wanglab.hku.hk/ChiP-Array) (76). A hierarchical Bcl-3 transcriptional 
regulation network during disuse atrophy is depicted in Figure 4.7. Among the 
138 direct target genes of Bcl-3, four transcription factors (pink circles) , Foxo1 , 
Fox03, Nfic and Pou2f1, were considered as important regulation nodules 
downstream of Bcl-3 (blue octagon) during disuse atrophy. This was based on 
the finding that over-represented binding sites for these 4 transcription factors 
were identified in -8kb to +2kb promoter region of the 235 Bcl-3 indirect genes 
(grey circles), which showed increased mRNA expression (by microarray) but 
lacked of increased Bcl-3 binding due to unloading (ChiP-seq) . Therefore, the 
Bcl-3 transcriptional regulation network during disuse atrophy includes 134 Bcl-3 
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direct targets genes encoding for proteins important for protein catabolism or 
glucose metabolism (shown by iPAGE analysis) and 4 transcription factors 
(Foxo1 , Fox03, Nfic and Pou2f1 ), whose activation by Bcl-3 may be responsible 
for upregulating Bcl-3 indirect targets. 
4.3 Discussion 
Bcl-3 and p50 have been shown to be required for disuse muscle atrophy. 
However, their downstream targets to carry out muscle atrophy remain largely 
unknown. In the previous chapter, we identified 240 Bcl-3 and p50 targets in 
disuse atrophy by comparing microarray data of weight-bearing and unloaded 
muscles from wild-type and either gene knockout. Although we were not able to 
differentiate direct gene targets from indirect targets , fourteen target genes 
identified by our microarray were chosen for studying Bcl-3 or p50 binding to 
conserved KB sites in the promoter region by ChiP-PCR. Seven genes with 
known or inferred function in atrophy were shown to be bound by Bcl-3 at KB 
sites. Since p50 bound to KB sites in weight-bearing muscles, and unloading 
either increased or did not change p50 binding, p50 was not a good candidate for 
finding direct targets important for eliciting atrophy. Bcl-3, on the other hand, is 
the main regulator in the Bcl-3/ p50 homodimer complex for transactivating 
genes for inducing disuse muscle atrophy. Because of the inherent limitations of 
ChiP-PCR such as low resolution of TFBS and only one TFBS was examined per 
PCR primer designed, the major aim of this study is to identify Bcl-3 direct targets 
in disuse atrophy at a genome-wide level. This was done by identifying Bcl-3 
binding in chromatin from weight-bearing and unloaded muscles from wild-type 
mice using ChiP-seq. Genes with Bcl-3 peaks in promoter regions and 
increased mRNA expression due to unloading were considered as Bcl-3 direct 
target genes. 
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The most impressive finding from the ChiP-seq results is the degree to 
which protein catabolic pathways were targeted by the Bcl-3 regulatory network. 
The impartial gene ontology algorithm of iPAGE indicated that protein catabolism 
or its regulation was the most enriched functional category represented by the 
genes with Bcl-3 peaks in the promoter region due to unloading (11 GO terms 
out of 14 total identified). There were 14 genes in the protein catabolism 
category identified by iPAGE, and six of these genes encode E3 ubiquitin protein 
ligases. Of interest is that one of the E3s is Ubr1, the gene also known as E3a 
ligase. It is one of the major recognition ligases for ubiquitinating proteins that 
have destabilizing amino acids at their N termini. It is noted in the literature that 
the ubiquitination present in atrophy is largely due to the activation of the N-end 
rule pathway (42,97). A knockout of Ubr1 shows muscle-specific abrogation of 
N-end rule ubiquitination (98). Another target gene of Bcl-3 and theN-end rule 
pathway is arginyltransferase, the enzyme encoded by the Ate1 gene, which puts 
an arginine destabilizing amino acid on the amino termini populated by aspartic 
and glutamic acids and by oxidized cysteine (99). Finally, our ChiP-seq data 
also showed that Bcl-3 and p50 both bound to KB site 3.1 kb upstream of the 
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MuRF1 transcription start site during unloading. MuRF1 is a muscle-specific E3 
ligase whose function has been studied extensively and shown to target muscle 
thick filaments for degradation. However, the regulation of MuRF1 gene 
expression is not well understood. We do not know if increased Bcl-3 or p50 
binding are required for MuRF1 transactivation but both transcription factors are 
required for MuRF1 expression in disuse atrophy (28) . Additional experiments 
using deletion or mutant constructs of MuRF1 promoter reporter are needed to 
understand MuRF1 regulation during muscle atrophy. 
A number of GO pathways identified in our results are involved with 
glucose metabolism, and the genes include phosphofructokinase, the rate 
limiting enzyme of the glycolysis pathway, and muscle glycogen phosphorylase, 
the enzyme responsible for liberating glucose from muscle glycogen stores. In a 
separate study, phosphofructokinase was found upregulated in unloaded rat 
muscles, reflecting a change to increased glycolysis and use of glycogen stores 
with disuse (1 00). Two other glycolytic genes, not part of the iPAGE results , also 
showed Bcl-3 peaks in their promoters due to unloading , hexokinase (HK2) and 
aldolase A (AidoA). Finally, the GO terms include 7 GO terms involved in 
development and morphogenesis. The genes from these pathways include two 
affecting the Wnt pathway (Tcf712 and Ape) . The Tcf712 gene (also known as 
Tcf4) has recently received considerable attention as it is thought to be 
significantly linked to type II diabetes. This form of diabetes is characterized by 
insulin resistance and changes in glucose metabolism, especially in muscle 
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(1 01 ). Ape, acts as a Wnt antagonist with direct effects on Tcf712 (1 02). Psap is 
a precursor of the sapos ins which regulate lysosomal degradation of 
sphingolipids. Sphingolipids appear to be directly involved in both muscle 
atrophy (1 03) and insulin resistance (1 04) . 
Since we were interested in identifying the direct target genes of Bcl-3 in 
disuse atrophy and exploring the networks regulated by Bcl-3 direct targets, 
ChiP-Array (76) (http://wanglab.hku.hk/ChiP-Array) algorithm was used to 
integrate data from Bcl-3 ChiP-seq and gene expression profiling during 
unloading. ChiP-Array results showed that in addition to the 138 Bcl-3 direct 
targets in disuse atrophy are Fox01, Fox03, Pou2f1 , and Nfic transcription 
factors , which in turn upregulated mRNA expression of 234 genes. Several 
studies have implied the importance of FoxO in muscle atrophy. For example, 
overexpressing constitutively active Fox03 was shown to be sufficient for 
increasing atrogin-1 expression and inducing skeletal muscle atrophy (39), 
whereas expressing a dominant-negative form of FoxQ1/3 significantly 
attenuated muscle atrophy due to immobilization (105). However, gene networks 
of Fox01/3 or other transcription factors have not been identified. The 
hierarchical activation of these four transcription factors by Bcl-3 adds to the 
complexity of Bcl-3 transcriptional network, which is required for eliciting the 
atrophy processes following unloading stimuli. 
Based on the binding of Bcl-3 to promoter regions of genes during muscle 
atrophy it has become clear that Bcl-3 regulates a transcriptional network of the 
genes involved in muscle catabolism and metabolism. These data provide the 
molecular evidence to explain why Bcl-3 knockout mice do not show unloading 
atrophy. Bcl-3 is therefore a global regulator both of the proteolysis and the 
change in energy metabolism that are essential components of muscle atrophy 
due to disuse. 
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Table 4.1 The gene lists in each enriched GO category from iPAGE analysis 
GO category Gene Name Function 
Protein catabolism Adam17 Activates some membrane receptors 
(11 GO terms) Arih2 E31igase 
Ate1 Arginyl transferase 
Cul2 Component of ECS ubiquitination 
Fbxo6 E31igase 
Hspa5 Hsp 70 family member 
Itch E31igase 
Ppt1 Lysosomal degradation 
Psen1 lntramembrane protein cleavage 
Rlim Ring finger protein 
Sod1 Reactive radical destroyer 
Trim63 Muscle E3 ligase (MuRF1) 
Ubr1 n-recognin for N rule proteolysis 
Usp22 Ubiquitin thioesterase 
Development Ape Wnt antagonist 
(7 GO terms) Psap Sphingolipid recognition in lysosomes 
Tcf712 Wnt signaling glucose metabolism 
Eya3 Essential for myogenin activity 
Glucose metabolism Pfkl Phosphofructokinase 
(4 GO terms) Pygm Glycogen phosphorylase 
Phosphatases Dusp3 Phosphatase, MAPK inhibitor 
(1 GO term) Ppm1g Phosphatase 
Ppp1cb Phosphatase catalytic subunit 
Ppp1 r12a Regulation of Ppp1 c 
Table 4.2 qPCR of selected proteolysis genes with increased Bcl-3 promoter 
binding. 
Gene s~mbol Fold change 
Arih2 2.1 
Ate1 1.5 
Fbxo6 1.8 
Itch 1.4 
Rlim 1.6 
Rnf13 1.5 
Psmb7 1.9 
Sod1 1.8 
Trim63 2.0 
Ubb 1.8 
Ubr1 1.7 
Fold change, control vs. unloaded 
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Table 4.3 GO terms enriched by 138 Bcl-3 direct targets in disuse atrophy 
Fold 
Term enrichment 
Metabolic process 
G0:0045934-negative regulation of nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process 3.6 
G0:0051172-negative regulation of nitrogen compound metabolic 
process 3.6 
G0:0030163-protein catabolic process 3.4 
G0:0009892-negative regulation of metabolic process 3.2 
G0:0031324-negative regulation of cellular metabolic process 3.2 
G0:001 0605-negative regulation of macromolecule metabolic process 3.1 
G0:0009057-macromolecule catabolic process 3.1 
G0:0006793-phosphorus metabolic process 2.5 
G0:0006796-phosphate metabolic process 2.5 
G0:0044267-cellular protein metabolic process 2.2 
G0:0019219-regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 2.0 
G0:0051171-regulation of nitrogen compound metabolic process 2.0 
G0:0019538-protein metabolic process 1.9 
G0:0044260-cellular macromolecule metabolic process 1.9 
G0:0080090-regulation of primary metabolic process 1.9 
G0:0060255-regulation of macromolecule metabolic process 1.9 
G0:0006139-nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 1.8 
G0:0031323-regulation of cellular metabolic process 1.8 
G0:0043170-macromolecule metabolic process 1.8 
80:0019222-regulation of metabolic process 1.7 
G0:0034641-cellular nitrogen compound metabolic process 1.7 
G0:0006807-nitrogen compound metabolic process 1.7 
G0:0044237-cellular metabolic process 1.6 
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G0:0044238-primary metabolic process I 1.5 
Gene expression 
G0:001 0629-negative regulation of gene expression 3.5 
G0:0006350-transcription 2.3 
G0:001 0467-gene expression 2.1 
G0:0045449-regulation of transcription 2.0 
G0:001 0468-regulation of gene expression 2.0 
Biosynthetic process 
G0:0009890-negative regulation of biosynthetic process 3.7 
G0:001 0558-negative regulation of macromolecule biosynthetic process 3.4 
G0:0034645-cellular macromolecule biosynthetic process 2.0 
G0:0009059-macromolecule biosynthetic process 2.0 
G0:001 0556-regulation of macromolecule biosynthetic process 2.0 
G0:0009889-regulation of biosynthetic process 2.0 
G0:0031326-regulation of cellular biosynthetic process 1.9 
G0:0044249-cellular biosynthetic process 1.9 
G0:0009058-biosynthetic process 1.8 
Chromatin modification/ organization 
G0:0016568-chromatin modification 4.9 
G0:0006325-chromatin organization 4.2 
G0:0051276-chromosome organization 3.6 
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Figure 4.1 Even distribution of 49,000 Bcl-3 peaks over the mouse genome. Red 
bars show the location of Bcl-3 binding peaks in disuse atrophy on chromosome. 
The x-axis represents the actual chromosome sizes. The height of the vertical 
line indicates peak heights; the taller the red bar is, the greater the read counts at 
the peak summit. 
~2.5 ~2 
- Bcl-3 peaks 
Random peaks 
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Figure 4.2 Distribution of Bcl-3 peaks relative to the transcription start site 
(TSS) of the associated gene. Proportion of genes with a peak relative to entire 
number of genes in mouse genome is plotted against the distance of peaks 
relative to TSS (between -2.5kb to +2.5kb from TSS). Blue represents the plot of 
Bcl-3 peaks in disuse atrophy and grey represents the plot of random peaks 
found in the input chromatin from unloaded muscle. 
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Figure 4.3 Phylogenomic conservation for the 2,817 Bcl-3 peaks in disuse atrophy. 
The average PhastCon scores of the sequences surrounding the Bcl-3 peaks ( -1500bp 
to +1500bp) was plotted to show that conservation is the highest at the center of the 
peaks. PhastCon measures the sequence similarity for 31 placental mammals based on 
their phylogenetic distance from mice; a Phastcon score of 1.0 reflects a perfect identity 
in all 31 species. 
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Figure 4.4 Distribution of the binding peaks in gene parts. (A) ChiPseeqer genomic 
annotation for the 2,817 Bcl-3 peaks showing 2-fold or more increase in sequence reads 
enriched by Bcl-3 antisera in the unloaded muscle compared to the weight-bearing 
muscle. (B) ChiPseeqer genomic annotation for 1,594 random peaks found in the 
sequence reads in the unloaded muscle input chromatin, which was fragmented and 
used to create a library without immuneprecipitation. The same peak finding parameters 
in ChiPseeqer were set to find the 2,817 unloading induced Bcl-3 peaks (A) and 1,594 
random peaks (B). 
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Figure 4.5 GO terms enriched in genes with Bcl-3 peaks during unloading. iPAGE 
analysis identified 23 GO terms over-represented (red bar) by genes with Bcl-3 peaks in 
promoters due to muscle unloading. Text labeling indicates the name of the GO term 
and the associated GO identification number. 
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Figure 4.6 Increased Bcl-3 binding near the transcription start site (TSS) of Ubr1 
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(A) and Ate1 (B) following unloading. ChiP-seq results showed Bcl-3 binding profile 
at Ubr1 (chromosome 2) and Ate1 (chromosome 7) gene locus in plantaris muscles from 
weight-bearing (WB) or hind limb unloading (HU) mice, visualized by the Integrated 
Genomics Viewer (IGV). In both panels, the top line represented the genomic size and 
location surrounding the TSS of the region. Vertical ticks are spaced 500 bp apart . .The 
seven rows in each part of the figure are labeled as follows: gene, the location and 
orientation for the gene of interest in chromosome; Conservation, the sequence similarity 
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among placental mammals shown as Phastcons; Ch!Pseeqer peak, the location of the 
Bcl-3 peak identified by the ChiPseeqer algorithm; HU Bc/-3, a representation of the 
sequence alignments for the Bcl-3 ChiPseq in the unloaded muscle; WB Bc/-3, a 
representation of the sequence alignments for the Bcl-3 ChiPseq in the weight-bearing 
muscle; Input, a representation of the sequence alignments where no antibody was used 
to enrich chromatin from unloaded muscle; NF-KB site, the location for an NF-KB 
consensus site identified using JASPAR matrices. 
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Figure 4.7 Increased Bcl-3 and PSO binding at the MuRF1 promoter region 
following unloading. Bcl-3 and p50 binding profile in MuRF1 promoter region in 
unloaded plantaris muscles from ChiP-seq analysis. In silica analysis showed high 
conservation among mammalian sequence at 3.1 kb and 4.2 kb upstream MuRF1 
promoter region as shown by Phastacon scores in the Conservation panel. The panel 
below represents ChiPseq data, which showed sequence reads for Bcl-3 and p50 in 
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unloaded muscles located at -3.1 kb MuRF1 promoter region, but not at -4.2kb upstream 
MuRF1 TSS. ChiPseeqer identified Bcl-3 and p50 peaks at -3.1 kb MuRF1 promoter 
region which overlap with one of the three JASPAR defined NF-KB sites in MuRF1 
promoter region (bottom panel). 
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Figure 4.8 Transcriptional regulation network of Bcl-3 in unloading induced 
muscle atrophy. ChiP array algorithm combined results from gene expression profile, 
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Bcl-3 ChiP-seq, and in silica analysis of transcription factor binding site to identify a Bcl-
3 transcriptional regulation network during unloading atrophy. Unloading induced 
activation of Bcl-3 (denoted in blue hexagon) directly binds and activates mRNA 
expression of 138 genes (yellow and pink circles) . Among these 138 direct target 
genes, Fox01 , Fox03, Pou2f1 and Nfic (in pink circles) showed enriched DNA binding 
sites in promoter region for the Bcl-3 indirect target genes (shown in grey circle 
connected to the pink circles) , which gene expression was increased due to unloading 
but lacked a correlated increase in Bcl-3 binding (shown by ChiP-seq). This complex 
Bcl-3 transcriptional network showed a hierarchical regulation of direct or indirect target 
genes activation by Bcl-3, which is required for inducing muscle atrophy due to 
unloading. 
Chapter 5 Analysis of the promoter region of a Bcl-3 target gene in 
disuse atrophy 
5.1 Introduction 
73 
The muscle-specific ring finger protein1 (MuRF1 or Trim63) is an E3 
ubiquitin ligase that has been shown to be a key regulator of protein degradation 
during skeletal muscle atrophy. Increased MuRF1 expression has been reported 
in multiple types of muscle atrophy such as denervation (30), limb immobilization 
(33) , biomechanical unloading (28,35), starvation (1 06), steroid administration 
(38) and Lewis lung tumor inoculation induced cancer cachexia (1 06). Knockout 
of the MuRF1 gene has been reported to spare muscle mass by 25-36% in 
response to denervation or glucocorticoid treatment (30, 1 07). The reduction in 
maximal force generation due to TNF-a treatment in wild-type mice was also 
reversed in MuRF1 knockout mice (1 08). Several studies suggest that MuRF1 
ubiquitates muscle proteins such as myosin heavy chain (96), myosin binding 
protein C (MyBP-C), myosin light chains 1 and 2 (MyLC 1/2) for degradation 
during muscle atrophy (31) . Others reported that MuRF1 regulates energy 
metabolism and inhibits protein synthesis during skeletal muscle atrophy 
(107,109,110). 
Despite the number of studies on the role of MuRF1 in muscle atrophy, 
there is little known about the regulation of MuRF1 gene activation during atrophy. 
Moresi eta/. (37) reported that MuRF1 activation was significantly attenuated in 
myogenin knockout mice following denervation but not following fasting, and, 
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MuRF1 promoter activation due to muscle denervation was abolished when all 
three myogenin binding sites within the 600bp promoter were mutagenized. 
However, different MuRF1 regulation mechanisms could be involved depending 
on the atrophy trigger. Waddell eta/. (38) reported that both Fox01 binding sites 
and glucocorticoid response elements within the 500bp MuRF1 promoter were 
required for inducing MuRF1 reporter activation following glucocorticoid 
administration in C2C12 myotubes. Using a larger region of the MuRF1 gene, 
Files eta/. (29) showed increased MuRF1 induction in atrophied tibialis anterior 
muscles following acute lung injury in the reporter containing the 5kb MuRF1 
promoter compared to the shorter reporter construct containing just 500bp. The 
authors hypothesized that multiple NF-KB sites in the distal 5' end of MuRF1 
promoter could be responsible for the observed MuRF1 reporter activation . Cai 
eta/. (36) reported that increased activation of a MuRF1 promoter reporter 
(4.4kb) due to cytokine treatments in C2C12 myotubes was abolished by NF-KB 
inhibition via overexpressing IKBa superrepressor. The latter two studies suggest 
that NF-KB mediated transcription is involved in MuRF1 transactivation during 
atrophy but primary evidence is lacking. We found that increased MuRF1 mRNA 
expression due to unloading was abolished in mice lacking either Bcl-3 or p50, 
and , ChiP-seq data showed increased Bcl-3 and p50 binding in the MuRF1 
promoter after 5 days of unloading (28, 111 ). 
The purpose of the present study is to identify the regulatory sites required 
for the transactivation of the MuRF1 gene during the removal of weight-bearing, 
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a clinically relevant model of skeletal muscle atrophy. In this study, we made 
site-specific mutant constructs of the 4.4kb MuRF1 promoter to test the 
requirement of NF-KB and FoxO sites for MuRF1 transactivation during muscle 
unloading atrophy. An advantage of this approach is that the wild-type and 
mutant constructs were tested in whole muscle during physiological atrophy, and 
we used site specific mutants rather than deletion mutants. This work provides 
primary evidence that NF- KB sites but not FoxO sites are required for MuRF1 
upregulation during disuse atrophy, supporting the idea that different transcription 
factors are involved in MuRF1 gene regulation depending on the trigger of 
muscle atrophy. 
5.2 Results 
5.2.1 In silico analysis of transcription factor binding sites in the MuRF1 
promoter 
To identify transcription factor binding sites (TFBS) required for inducing 
MuRF1 activation during atrophy, 4.4kb of MuRF1 promoter sequence from 
mouse and human were aligned and compared. Three regions in the MuRF1 
promoter showed greater than 50% sequence conservation between mouse and 
human, located at 0- -400bp, -3kb- -3.5kb, and -4--4.5kb upstream of the 
MuRF1 transcription start site (TSS). There were 3 conserved predicted NF-KB 
binding sites located at 3.1, 4.1 and 4.2kb upstream of mouse MuRF1 TSS but 
only the NF-KB binding site at -3.1 kb upstream of MuRF1 was considered as an 
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over-represented TFBS by the Whole Genome RVista algorithm 
(http://genome.lbl.gov/vista/citeus.shtml) (77). We also found 4 conserved 
putative FoxO binding sites at 3kb, 2.5kb, 185bp, and 24bp upstream of the 
MuRF1 transcription start site and 5 myogenin binding sites shown schematically 
in Figure 5.1. 
5.2.2 NFKB binding sites, but not FoxO binding sites, are important for 
upregulation of MuRF reporter activity in unloading atrophy 
To understand MuRF1 transactivation during atrophy, we obtained a 4.4kb 
mouse MuRF1 promoter reporter construct from Dr. Cai (36) and transiently 
transfected it into rat soleus muscle. There was an approximately 4-fold 3-fold 
increase in MuRF1 reporter activity (MuRF1) in atrophied soleus muscles 
following 5 days of unloading (HU) compared to the weight-bearing muscles 
(Figure 5.2). To determine whether the distal 5' promoter sequence of MuRF1 is 
important for its transactivation in disuse atrophy as implied by Files eta/. (29), a 
MuRF1 reporter deletion construct (5'Ll MuRF1) was made, which lacks the distal 
5' (2 .1 kb) promoter sequence of the 4.4kb MuRF1 promoter. The up regulated 
MuRF1 reporter activity due to unloading was abolished in muscles transfected 
with 5'Ll MuRF1, indicating that the distal 2.1 kb sequence of the MuRF1 
promoter is required for MuRF1 transactivation due to unloading. Thus, we 
examined the distal 2.1 kb sequence of MuRF1 promoter for conserved 
transcription factor binding site (TFBS). We found that all 3 NF-KB binding sites, 
2 FoxO sites and 2 myogenin sites were deleted in LlMuRF1 , indicating that 
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these TFBS may be responsible for inducing MuRF1 activation due to unloading. 
To determine whether NF-KB or FoxO binding sites were required for 
inducing MuRF1 activation , MuRF1 promoter constructs were mutated at all 
three conserved NF-KB binding sites (KBmut_MuRF1) or all four FoxO binding 
sites (Fox0mut_MuRF1 ). Both wild-type and mutated MuRF1 promoter reporter 
constructs were transiently transfected into rat soleus and reporter activity was 
measured 5 days after unloading. We found that unloading-induced upregulation 
of MuRF1 reporter activity was abolished in the muscles transfected with the 
KBmut MuRF1 construct but was unchanged in the FoxOmut MuRF1 construct 
- -
(Figure 5.3). These results show that NF-KB binding sites are required for 
MuRF1 transactivation due to unloading but FoxO sites are not required . 
5.2.3 Activation of MuRF1 promoter dependent reporter was dependent on the 
distal two KB sites 
To test which NF-KB binding sites are required for inducing MuRF1 
expression during unloading atrophy. Each KB site within the 4.4kb MuRF1 
promoter region of the reporter was mutagenized and then the reporters were 
injected to the rat soleus. As shown in Figure 5.4, we found that MuRF1 reporter 
with the 3' most KB site mutagenized (KB3mut_MuRF1) showed a similar 
increase in reporter activation due to unloading compared to the wild-type 
MuRF1 reporter. However, MuRF1 reporter activation due to unloading was 
abolished in reporters with either of the two distal KB sites mutated 
(KB1 mut_MuRF1 and KB2mut_MuRF1 ). 
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5.3 Discussion 
Although increased MuRF1 gene expression in various types of muscle 
atrophy and may be responsible for targeting muscle proteins for degradation, 
the transcriptional activation of this gene is not well understood. A few groups 
have studied MuRF1 regulation in atrophy (37,38), but they studied the 
requirement of a TFBS in the short proximal MuRF1 promoter (-500bp), a 
fragment that we show is not activated due to unloading atrophy (Figure 5.2). 
While previous work suggested that NF-KB is involved in MuRF1 activation 
(29,36) there is no primary evidence to support the requirement of NF-KB binding 
sites for inducing MuRF1 expression during atrophy. 
Here we provide the first direct evidence that the NF-KB sites are required 
for MuRF1 transactivation following unloading-induced muscle atrophy. This 
result is consistent with our previous finding that MuRF1 mRNA upregulation due 
to unloading is abolished in mice deficient in p50, a transcription factor of the NF-
KB family, or Bcl-3, a p50 transcriptional co-activator (28) . In another paper (112), 
ChiP-seq data identified increased Bcl-3 and p50 binding to the MuRF1 gene in 
unloading-induced skeletal muscle atrophy. The site of increased binding 
however, was the KB site located at 3.1 kb upstream of the MuRF1 transcription 
start site which when mutagenized had no effect on MuRF1 activation with 
unloading. It is therefore surprising that the distal two NF-KB sites in the MuRF1 
promoter, instead of the proximal site bound by Bcl-3 and p50, were required for 
gene activation due to unloading (Figure 5.4). While it is possible that increased 
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Bcl-3 binding does not confer target gene (e.g. MuRF1) transactivation , it should 
be noted that our promoter reporter measures transactivation of the promoter in 
an extra-chromosomal context, which may not reflect the natural protein binding 
on intact chromatin as shown by ChiP-seq. Therefore, we interpret our site-
directed mutagenesis data as suggesting that two KB sites function coordinately 
as a single module that is required for MuRF1 gene activation as shown in 
Figure 5.5. Since Bcl-3 does not directly bind to DNA, Bcl-3 may bind to dimers 
of p50 where interaction may occur next to each other via chromatin folding . 
This model has been previously postulated to regulate MCP-1 and IP-10 
expression where one KB site determine specificity of KB dimers, the other 
recruits specific co-factors, and together, the two KB sites determine whether 
expression of target gene will be activated or repressed (113). However, more 
experiments need to be done to fit this model into our system. 
The discrepancies regarding to which NF-KB site is required for MuRF1 
transactivation during unloading atrophy between the ChiP-seq and MuRF1 
promoter reporter results could also be attributed to the differences of the two 
assays. For instance, the efficiency of each step in ChiP-seq , including cross-
linking , sonication , antibody enrichment, and DNA sequencing , greatly affects the 
protein-DNA binding results . For instance, we fixed the protein-chromatin 
interaction in 1% formaldehyde, which has a relatively short cross-linking spacer 
arm for cross-linking nuclear components located within 2A of each other. Thus, 
it could be ineffective in capturing the association of Bcl-3 to either of the 5' distal 
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NF-KB sites because Bcl-3 located more distant from these 2 sites. It was also 
possible that Bcl-3 bound more loosely to the two 5' distal NF-KB sites, therefore, 
Bcl-3 interaction with those two sites were disrupted during sonication but 
preferentially preserved at the most 3' NF-KB site. Besides, since chromatins 
were fixed in physiological state, the C-terminus epitope of Bcl-3 could be 
disguised in a complicated DNA-protein configuration at the two 5' distal NF-KB 
sites, but not the proximal NF-KB site. Therefore, it prevented the distal 
chromatin from being enriched by the SC-185x Bcl-3 antibodies. On the other 
hand, reporter assay has the disadvantages of longer half-life (ranging from 3-
12hr) compared to ChiP-seq, competition of transcriptional activation complexes 
among multiple copies of reporter transfected into muscles cells, and lack of the 
DNA folding configurations as it is in the nature chromosomal context, etc. 
Future experiments studying Bcl-3 and p50 binding on NF-KB sites in promoter of 
the MuRF1 reporter, profiling Bcl-3 or p50 binding dynamics in MuRF1 promoter 
at multiple time points, measuring MuRF1 reporter activity in Bcl-3 or p50 
knockout mice, or high resolution fluorescent in situ hybridization for co-
localization of protein-DNA interaction will help us to further identify which of the 
NF-KB sites and the NF-KB transcription factors or co-activators are essential for 
transactivating MuRF1 gene. 
Many studies have implicated the activation of the FoxO transcription 
factor family during muscle atrophy as important for regulating proteolytic gene 
expression. Increased MuRF1 mRNA expression in atrophied muscles due to 
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tumor bearing or sepsis was abolished while overexpressing dominant negative 
FoxO (1 06). Specifically, removal of Fox01 or Fox01 binding sites has been 
reported to abolish MuRF1 mRNA in dexamethasone treated myotubes (38, 114) 
However, our results of transient transfections of the 4.4kb MuRF1 promoter 
reporter with or without mutagenizing four FoxO binding sites showed that FoxO 
signaling was not required for transcriptional activation of MuRF1 due to 
unloading. Our data support a model where increases in MuRF1 expression 
during atrophy are regulated indirectly by FoxO transcription factors or that other 
co-factors are required for cooperative activation of MuRF1. While the 
discrepancy between our result and others may reflect that MuRF1 regulation is 
specifically dependent on the atrophy triggers or the model of muscle atrophy 
studied, we do not think glucocorticoid receptor and Fox01 work synergistically 
to activate MuRF1 expression in disuse atrophy as previously implicated in 
dexamethasone treated C2C12 myotubes (38). This is because previous studies 
have shown that glucocorticoid treatment enhanced unloading-induced muscle 
atrophy (115). Glucocorticoid administration-induced muscle atrophy not only 
activated a very different gene expression pattern compared to unloading-
induced muscle atrophy (35, 116), but it also increased myofibrillar and stromal 
protein contents which were not observed in unloaded muscles (115). 
In summary, our results demonstrate that removal of the distal two KB 
sites in the MuRF1 promoter is sufficient to abolish its transactivation due to 
unloading. Further experiments are needed to determine how KB sites interact 
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with each other to recruit Bcl-3 and p50 required for MuRF1 transactivation or if 
other cofactors are involved in order to fully understand the regulation of MuRF1 
during atrophy. 
I~ 
Myogen in I I I 
I 
I 
I II 
I 
83 
MuRF1 
% seqt.~ence r-L-------------------------.,...----'c::;J100% 
C(U'IServatiOn . ~ ,-. • ..-1$, r''- ,., ...... ~.. ,.....~, h ,...,. , . 50% 
l 38S6k 33&S7k 339SBk · 33969k 33870k 33871 k 
Figure 5.1 Sequence alignment and transcription factor binding sites within the 
5kb MuRF1 promoter region. rVISTA analysis was performed to compare sequence 
conservation between mouse and human genome at the 5kb promoter region of MuRF1 . 
The result was shown as a histogram at the bottom panel where MuRF1 transcription 
start site (TSS) was plotted as a blue arrow pointing to the right. Within the mouse 5kb 
MuRF1 promoter region, there were 4 conserved regions showing 75% mouse/ human 
sequence conservation , which were located at 4.6kb, 4.2kb, 3.1 kb, and 185bp upstream 
of MuRF1 TSS (percentage of conservation were indicated by the pink area) . In sifico 
analysis of transcription factor binding sites by rVISTA showed three NF-KB binding sites 
(yellow boxes), four FoxO sites (blue boxes) , and five myogenin binding sites (brown 
boxes), which were plotted against the mouse genome at the bottom panel. 
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Figure 5.2 Increased MuRF1 promoter reporter activity due to unloading was 
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abolished .by removing the distal 5'end 2.1 kb sequence in the MuRF1 promoter. A 
2.3kb MuRF1 promoter reporter (denoted as 5'ilMuRF1) was made by removing the 
distal 5'-end of 2.1 kb promoter sequence from the wild-type MuRF1 promoter reporter 
(MuRF1 ), which contains the 4.4kb MuRF1 promoter sequence to drive luciferase 
expression. Fifty micrograms of the wild-type MuRF1 promoter reporter (MuRF1) or 
5'ilMuRF1 were transfected into rat soleus muscles. 16 hours later, rats were 
randomized into weight-bearing (WB) or hind limb unloading groups (HU). After five 
days of WB or HU, whole tissue lysates were isolated from soleus muscles for luciferase 
activity measurement. MuRF1 promoter reporter activity of each group was plotted as a 
fold change compared to the average luciferase activity measured from weight-bearing 
muscles. 
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Figure 5.3 NF-KB binding sites, but not FoxO binding sites, were required for 
MuRF1 promoter reporter activation during unloading atrophy. Five days of hind 
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limb unloading upregulated the wild-type MuRF1 promoter reporter (MuRF1) activity by 
2.5-fold, which was abolished by removing all three NF-KB binding sites in the 4.4kb 
wild-type MuRF1 promoter sequence (KBmut_MuRF1) by site directed mutagenesis. 
Removing the four FoxO sites within the 4.4kb MuRF1 promoter sequence 
(FoxOmut_MuRF1) by site directed mutagenesis failed to abolish the upregulated 
MuRF1 promoter reporter activity due to unloading. 
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Figure 5.4 The distal two NF-KB sites were required for inducing MuRF1 promoter 
reporter activity following 5-days of unloading. Each of the three NF-KB binding 
sites in the 4.4kb MuRF1 promoter reporter was mutagenized and then transfected into 
rat soleus muscles to test their requirements for inducing MuRF1 activation due to 
unloading. Mutagenizing either of the two 5' distal NF-KB binding sites (K81 mut_MuRF1 
or KB2mut_MuRF1) significantly abolished the upregulation of wild-type MuRF1 
(MuRF1) reporter activity due to unloading, whereas there was still a significant 
upregulation of reporter activity found in the KB3mut_MuRF1 reporter which contained a 
mutated KB site at 3.1 kb upstream of the MuRF1 TSS. Reporter activity was reported as 
a fold change of luciferase activity measured in the unloaded muscles compared to the 
weight-bearing control of each reporter construct. 
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Figure 5.5 Multiple KB sites function together to transactivate MuRF1 expression 
during unloading muscle atrophy. Reporter activity and ChiP-seq results for MuRF1 
promoter led us to postulate a model shown here. In the genomic environment, MuRF1 
promoter sequence could be folded in a loop configuration that tetramers of NF-KB 
transcription factors bound to two KB sites and function coordinately as a single module 
to regulate MuRF1 gene activation. Following unloading, there were increased binding 
of Bcl-3 and p50 at the most 3' KB site, whereas either of the distal 5' NF-KB sites is 
required for MuRF1 transactivation by stabilizing the Bcl-3/ p50 homodimer complex in 
the tetramer possibly via .recruiting other co-activators. 
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Chapter 6 Conclusions 
Skeletal muscle is the most abundant tissue in the body and it has the 
greatest reserve of protein and carbohydrate. In addition, it plays a significant 
role in acid-base balance and in the regulation of circulating glucose. Therefore, 
loss of skeletal muscle has many deleterious effects on animal function and 
health. Skeletal muscle atrophy is defined as a reduction in muscle mass, due to 
a decrease in the diameter of muscle fibers. It is associated with decreased 
protein synthesis, increased muscle degradation, and it is accompanied by a 
reduction in oxidative capacity, reduced insulin sensitivity, and weakness. 
However, we have only a limited understanding of how muscle atrophy is 
regulated. 
Depending on the atrophy trigger, different signaling pathways activate 
specific transcription factors that lead to the atrophied phenotype. Changes in 
protein synthesis and protein degradation rates can be regulated by post-
translational events. However, long-term changes in muscle size are regulated 
by sustained changes in gene expression. Thus, it is important to study the 
regulation of gene expression on a genome-wide level in order to understand the 
atrophy process. Recent advances in genome-wide expression profiling and the 
combination of chromatin immunoprecipitation (ChiP) with next-generation 
sequencing make it possible to study the transcriptional regulatory networks that 
regulate muscle atrophy. Transcriptional networks provide us with the genes 
whose protein products together elicit the atrophy processes. Also genome-wide 
identification of transcription factors and their downstream targets in a 
transcription regulatory network may lead to the discovery of, uncharacterized 
signaling pathways or cellular processes that are beneficial for developing 
therapeutic interventions against muscle atrophy. 
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To date, few transcription factors are known to be required for inducing 
muscle atrophy. For muscle disuse, the required transcription factors are the two 
studied in this work (Bcl-3 and p50) and FoxO. In cancer-induced muscle 
atrophy, recently roles for STAT3 (117), C/EBP~ (40), and FoxO (1 06) in muscle 
atrophy have been found using knock-out or expression of dominant-negative 
forms of transcription factors. However, the requirement of these transcription 
factors appears to be tumor-type specific and none of these studies identified the 
target genes of transcription factors on a genome-wide level (i.e., transcription 
networks). Previous studies from our laboratory have found that two NF-KB 
proteins, p50 and its co-transactivator Bcl-3, are required for disuse atrophy 
(4,56). The main focus of my dissertation is to identify on a genome-wide basis, 
the target genes bound by the p50 and Bcl-3 transcription factors during disuse 
(i.e., unloading) muscle atrophy. The identification of target genes in an 
unbiased and genome-wide fashion pinpoints the genes required to produce a 
skeletal muscle atrophy phenotype. This project represents the first study to use 
whole genome approaches to discover the target genes that elicit any type of 
muscle pathology, in this case biomechanical unloading atrophy. 
In Chapter 3, I identified p50 and Bc-3 target genes during disuse atrophy 
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by comparing gene expression changes in atrophying wild-type mice compared 
to that of non-atrophying p50 and Bcl-3 knockout mice using microarrays. 185 or 
240 direct or indirect target genes of p50 and Bcl-3, respectively, were identified 
in disuse atrophy, and these target genes were functionally involved in 
transcription , translation , signaling , protein catabolism and metabolisms. 
Approximately 30% of the identified p50 or Bcl-3 direct or indirect target genes 
had known or inferred function in skeletal muscle atrophy; 14 of these genes 
were studied in further detail using ChiP-PCR for direct p50 and Bcl-3 binding to 
putative NF-KB sites in the promoter region in muscles from wild-type mice. 
Seven of the atrophy associated genes studied showed increased Bcl-3 binding 
to NF-KB sites in the promoter region following disuse atrophy (i.e. MuRF1 , 
atrogin1 , ubc, ctsl , runx1 , tnfrsf12a and cxcl10), whereas the rest of the seven 
genes showed unaltered Bcl-3 binding in promoter by disuse atrophy. For those 
genes with increased Bcl-3 binding due to disuse atrophy, p50 binds at the same 
region where Bcl-3 bound to in both weight-bearing and unloaded muscles 
without a recognizable change of binding pattern in response to disuse atrophy. 
Since binding of p50 homodimers on NF-KB sites alone are transcriptionally 
repressive, which could be relieved by binding of transcriptional co-activators 
such as Bcl-3 (47) , we propose that Bcl-3 binding to p50 homodimers may be 
important in tlie development of disuse muscle atrophy through NF-KB-
dependent transcriptional upregulation of atrophy genes. This is supported by 
our microarray findings that all of the identified p50 target genes due to disuse 
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are also Bcl-3 target genes. 
Further evidence supporting the target genes of Bcl-3 come from the 
ChiP-seq results (Chapter 4). An unbiased functional annotation of genes with 
increased Bcl-3 binding in promoter regions following disuse atrophy showed that 
Bcl-3 primarily binds to promotes genes responsible for protein catabolism and 
glucose metabolism. Combining microarray and Bcl-3 ChiP-seq results, we 
identified Bcl-3 direct binding targets with increased gene expression in disuse 
atrophy, including several E3 ubiquitin ligases (i.e. MuRF1, Ubr1, and Arih2) and 
transcription factors important for activating muscle atrophy programs (i .e. Fox01, 
Fox03) (39). 
The ChiP-seq data reveals transcriptional networks regulated by Bcl-3 in 
disuse atrophy at a genome-wide level. As illustrated in Figure 6.1, Bcl-3 is the 
main driver of disuse muscle atrophy processes through direct activation of 
genes responsible for proteolysis and the change in energy metabolism, which 
are essential components of muscle atrophy. Furthermore, transcriptional 
regulation by Bcl-3 during disuse atrophy is amplified by the direct activation of 
other transcription factors with known or inferred functions in atrophy such as 
FoxO. It should be noted that several Bcl-3 binding partners have been identified 
in other cell types other than p50 such as p52 (118), PGC1a (53), Jab1 (119), 
Pirin (119) , Tip60 (119), etc. Since NF-KB is required for inducing disuse 
atrophy, it is likely that some Bcl-3 direct targets identified in this work involved in 
co-regulation of by other transcription factors whose activation is NF-KB 
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dependent. 
One identified Bcl-3 direct target gene, MuRF1 , was studied in further 
detail (Chapter 5) . ChiP-seq data showed a Bcl-3 binding peak located 3.3kb 
upstream MuRF1 transcriptional start site, at the location of an in silica NF-KB 
binding site. We also found a p50 binding peak in the same region using ChiP-
seq for p50. Although site directed mutagenesis of this Bcl-3/p50 binding site 
failed to attenuate MuRF1 promoter reporter activation following disuse atrophy, 
mutagenizing either of the two NF-KB sites -1 kb upstream of the Bcl-3 peak 
abolished MuRF1 transactivation due to disuse atrophy. This could mean that 
Bcl-3/ p50 homodimer complex transactivates MuRF1 expression in a looped 
chromatin configuration (Figure 5.5) as previously described by Leung eta/ (113) . 
This is the first work to study the multiple NF-KB sites in the promoter region of 
MuRF1 , and to identify those that are required for its transcription activation 
during disuse atrophy. 
We have identified, for the first time, genome-wide target genes of a 
transcriptional co-activator (Bcl-3) that are required for muscle atrophy. 
Computational analysis of the target genes revealed two functional networks of 
genes. The newly identified direct target genes of Bcl-3 in muscle atrophy were 
associated with protein catabolism and changes in energy metabolism. Since 
the ultimate goal of investigating Bcl-3/p50 target genes during muscle atrophy is 
to identify potential therapeutic targets, further work should focus on testing the 
requirement of Bcl-3/p50 for target gene physiological function in development of 
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muscle wasting. It is currently unknown whether Bcl-3 is required for other types 
of muscle atrophy. Since altered Bcl-3 expression was reported in muscle 
atrophy induced by diabetes (59), blockage of neuromuscular transmission (120) 
and C-26 cancer cachexia (121) , future experiments should be conducted to 
examine the requirement of Bcl-3/p50. Gene networks of other transcription 
factors involved in disuse and other causes of muscle atrophy are yet to be 
identified, using methods similar to the ones showed here, but will be of great 
interest in order to further improve our understanding of the mechanisms of 
skeletal muscle atrophy. 
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Figure 6.1 Bcl-3 transcription regulatory network during disuse muscle atrophy. 
In response to loss of biomechanical stimuli , Bcl-3 is activated in skeletal muscle which 
directly binds and upregulates gene expressions of two functional networks associated 
with protein catabolism and glucose metabolism. These Bcl-3 direct target genes 
contribute to the increased protein degradation and glucose metabolism, which is 
consistent with the clinical features of atrophying muscles following disuse. 
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Appendix 
Appendix 1 Complete list of atrophy genes that are target genes for p50 or Bcl-3. 
Feature Gene Name, Gene ID FC p50 Bcl-3 
target target 
Anti-oxidant 
1449106 at glutathione peroxidase 3, Gpx3 1.72 N y 
1451503_at nucleolar protein 3 (apoptosis repressor with 1.65 y y 
CARD domain) , Nol3 
1421148 a at Tia1 cytotoxic granule-associated RNA binding 1.51 y y 
-- I protein-like 1, Tia11 
1434557 at huntingtin interactinQ protein 1, Hip1 1.43 y y 
Binding 
1448760 at zinc finger protein 68, Zfp68 1.58 y y 
1419281 a at zinc finger protein 259, Zfp259 1.55 y y 
1417321 
-
at zinc finger, CCHC domain containing 7, 1.52 y y 
Zcchc7 
1426084 a at torsin A interactinQ protein 1, Tor1 aip1 1.46 N y 
1417088 at zinc finger protein 346, Zfp346 1.44 y y 
Cell adhesion 
1416039 x at cysteine rich protein 61, Cyr61 2.28 y y 
1453556 x at CD99 antigen, Cd99 1.65 y y 
1418393 a at integrin alpha 7, ltQa7 1.62 y y 
1421811_at thrombospondin 1 /// similar to 1.58 y y 
thrombospondin 1, Thbs1 
1419613 at collagen, type VII, alpha 1, Col7a1 1.56 y y 
1460302 at thrombospondin 1, Thbs1 1.46 N y 
1436042 at talin 1, Tln1 1.4 y y 
Cell cycle 
1424105 a at pituitary tumor-transforming 1, Pttg 1 3.14 y y 
1424638_at cyclin-dependent kinase inhibitor 1A (P21), 2.56 N y 
Cdkn1a 
1417850 at retinoblastoma 1, Rb1 2.23 y y 
1416028 a at hematological and neurological expressed 1.9 y y 
sequence 1, Hn1 
1417516 at DNA-damage inducible transcript 3, Ddit3 1.59 N y 
1417619_at growth arrest and DNA-damage-inducible, 1.59 y y 
!gamma interacting protein 1, Gadd45gip1 
Chromatin modification 
1420477 at nucleosome assembly protein 1-like 1, Nap111 2.21 y y 
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Feature Gene Name, Gene ID FC p50 Bcl-3 
tar~et target 
1424760 a at SET and MYND domain containing 2, Smyd2 1.95 N y 
1429038 at DET1 and DDB1 associated 1, Dda1 1.81 y y 
1426810 at ljumonji domain containing 1A, Jmjd1a 1.77 N y 
1420376_a_at H3 histone, family 3A /// H3 histone, family 38, 1.59 y y 
H3f3a /// H3f3b 
1451167 at coiled-coil domain containing 101 , Ccdc101 1.56 y y 
1437210 a at bromodomain containing 2, Brd2 1.53 N y 
1449080 at histone deacetylase 2, Hdac2 1.5 y y 
1418367 x at histone cluster 2, H3c1 1.5 y y 
1425591 a at chromatin modifying protein 2A, Chmp2a 1.43 y y 
Cytoskeleton 
1455493 at synaptic nuclear envelope 1, Syne1 1.8 N y 
1448665 at dystrophin, muscular dystrophy, Dmd 1.7 y y 
1451200 at kinesin family member 1 B, Kif1 b 1.57 y y 
1434937 at MYC binding protein 2, Mycbp2 1.55 N y 
1439463 x at high mobility group box 1 1.55 y y 
1450650 at myosin X, Myo10 1.51 y y 
1416499 a at dynactin 6, Dctn6 1.5 y y 
1418986 a at ubiquitously expressed transcript, Uxt 1.47 y y 
1417626_at phosphodiesterase 40 interacting protein 1.44 y y 
(myomegalin), Pde4dip 
1416179 a at radixin , Rdx 1.43 y y 
1428835 at myosin, heavy polypeptide 14, Myh14 1.43 y y 
Development 
1427201_at musculoskeletal, embryonic nuclear protein 1, 3.5 N y 
Mustn1 
1416067_at interferon-related developmental regulator 1, 2.7 y y 
lfrd1 
1420895_at transforming growth factor, beta receptor I, 1.75 N y 
Tgfbr1 
1423606 at periostin, osteoblast specific factor, Postn 1.72 N y 
1428853 at I patched homolog 1, Ptch1 1.63 y y 
1431475 a at homeo box A 10, Hoxa1 0 1.45 y y 
1448266 at endothelial differentiation-related factor 1, Edf1 1.4 y y 
Extracellular Matrix 
1426808 at lectin , galactose binding , soluble 3, Lgals3 5.33 N y 
Immune 
1428346_at TRAF type zinc finger domain containing 1 , 1.55 y y 
Trafd1 
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Feature Gene Name, Gene ID FC p50 Bcl-3 
target target 
1453256_at polymerase (RNA) Ill (DNA directed) 1.42 y y 
polype_Qtide G, Polr3c 
Metabolism 
1449526_a_at glycerophosphodiester phosphodiesterase 9.85 y y 
domain containing 3, Gdpd3 
1451290_at microtubule-associated protein 1 light chain 3 2.06 N y 
alpha, Map11c3a 
1434442 at starch binding domain 1, Stbd1 1.9 y y 
1450660 at 6-pyruvoyl-tetrahydropterin synthase, Pts 1.86 y y 
1448111 at cytidine 5'-triphosphate synthase 2, Gtps2 1.85 y y 
1434542_at glutamic pyruvate transaminase (alanine 1.8 N y 
aminotransferasel2, GQ1:2 
1456251 x at translocator protein, Tspo 1.74 y y 
1451257_at acyl-GoA synthetase long-chain family 1.73 N y 
member 6, Acsl6 
1448736_a_at hypoxanthine guanine phosphoribosyl 1.64 y y 
transferase 1, Hprt1 
1416432_at 6-phosphofructo-2-kinase/fructose-2,6- 1.62 N y 
biphosphatase 3, Pfkfb3 
1422902_s_at meningioma expressed antigen 5 1.61 N y 
(hyaluronidase), Mgea5 
1449968_s_at acyl-GoA thioesterase 9, Acot9 Ill acyl-GoA 1.61 y y 
thioesterase 10, Acot1 0 
1416352 s at glycoprotein, synaptic 2, Gpsn2 1.57 y y 
1425764_a_at branched chain aminotransferase 2, 1.57 y y 
mitochondrial, Bcat2 
1415965 at stearoyi-Goenzyme A desaturase 1, Scd1 1.56 y y 
1423215_at signal peptidase complex subunit 2 homolog 1.52 y y 
(S. cerevisiae) , Spcs2 
1448143_at aldehyde dehydrogenase 2, mitochondrial , 1.5 y y 
Aldh2 
1425515_at phosphatidylinositol 3-kinase, regulatory 1.48 N y 
subunit, polypeptide 1 (p85 alpha), Pik3r1 
1450966 at carnitine 0-octanoyltransferase, Grot 1.45 y y 
1452781_a_at Mpv17 transgene, kidney disease mutant/// 1.43 y y 
general transcription factor IIIG, polypeptide 2, 
beta, Gtf3c2 Ill Mpv17 
1422608 at cAMP-regulated phosphoprotein 19, Arpp19 1.42 y y 
1420502 at spermidine/spermine N 1-acetyl transferase 1, 1.42 y y 
Sat1 
1437711 x at ornithine decarboxylase, structural 1, Odc1 1.4 y y 
1448495_at tissue specific transplantation antigen P35B, 1.4 y y 
Tsta3 
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Others 
1448199 at ankyrin repeat domain 10, Ankrd10 2.4 N y 
1426464_at nuclear receptor subfamily 1, group D, 1.85 y y 
member 1, Nr1d1 
1433509 s at receptor accessory protein 1, Reep1 1.79 y y 
1439405 x at Cyclin N-terminal domain containing 1, Cntd1 1.54 y y 
143367 4_a_at small nucleolar RNA host gene (non-protein 1.52 y y 
coding) 1, Snhg1 
1428389 s at WD repeat domain 43, Wdr43 1.46 y y 
1424759 at arrestin domain containinQ 4, Arrdc4 1.45 y y 
1451442 at coiled-coil domain containing 104, Ccdc1 04 1.44 y y 
Muscle contraction 
1422580 at myosin , light polypeptide 4, My14 1.93 y y 
1450813 a at troponin I, skeletal , slow 1, Tnni1 1.47 y y 
1456623 at tropomyosin 1, alpha, Tpm1 1.41 y y 
Proliferation 
1426083_a_at B-cell translocation gene 1, anti-proliferative Ill 1.67 y y 
similar to myocardial vascular inhibition factor, 
Btg1 
1460542_s_at transformed mouse 3T3 cell double minute 4, 1.64 y y 
Mdm4 
Protein degradation 
1417522 at F-box protein 32, Fbxo32 2.85 N y 
1422650 a at RIO kinase 3 (yeast), Riok3 1.94 N y 
1417480 at f-box protein 9, Fbxo9 1.8 N y 
1451310 a at cathepsin L, Ctsl 1.61 N y 
1448824 at ubiquitin-conjugating enzyme E2, J1, Ube2j1 1.61 y y 
1453623 a at RAD23a homoloQ (S. cerevisiae) , Rad23a 1.53 y y 
1416290_a_at proteasome (prosome, macropain) 26S 1.53 y y 
subunit, ATPase, 4, Psmc4 
1422459_a_at proteasome (prosome, macropain) 26S 1.51 y y 
subunit, non-ATPase, 13, Psmd13 
1423568_at proteasome (prosome, macropain) subunit, 1.51 y y 
alpha type 7, Psma7 
1460698 a at SEC11 homolog C (S. cerevisiae), Sec11c 1.51 y y 
1423269_a_at neural precursor cell expressed, 1.47 y y 
developmentally down-regulated gene 4-like, 
Nedd41 
1451971 at cullin 4A, Cul4a 1.47 y y 
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1415831_at proteasome (prosome, macropain) 26S 1.47 y y 
subunit, non-ATPase, 2, Psmd2 
1426400 a at calpain, small subunit 1, Capns1 1.46 y y 
1448591 at cathepsin S, Ctss 1.46 y y 
1417052_at proteasome (prosome, macropain) subunit, 1.45 y y 
beta type 3, Psmb3 
1435431_at proteasome (prosome, macropain) assembly 1.44 y y 
chaperone 4, Psmg4 
1438984_x_at proteasome (prosome, macropain) subunit, 1.44 y y 
beta type 4, Psmb4 
1448883 at legumain, Lgmn 1.41 y y 
1425859_a_at proteasome (prosome, macropain) 26S 1.4 y y 
subunit, non-ATPase, 4, Psmd4 
1418020 s at carboxypeptidase D, Cpd 1.4 y y 
RNA processing 
1422885 at small nuclear ribonucleoprotein D3, Snrpd3 1.89 N y 
1454793_x_at DEAD (Asp-Giu-Aia-Asp) box polypeptide 5, 1.75 y y 
Ddx5 
1436494_x_at TRM1 tRNA methyltransferase 1 homolog (S. 1.66 y y 
cerevisiae), Trmt1 
1422849 a at poly(A) binding protein, nuclear 1, Pabpn1 1.64 y y 
1442744 at RNA binding motif protein 39, Rbm39 1.54 y y 
1426793_a_at ribosomal protein L 14 Ill similar to Ribosomal 1.52 y y 
protein L 14, Rpl14 
1434390_at Heterogeneous nuclear ribonucleoprotein U, 1.52 N y 
Hnrnpu 
1423130_a_at splicing factor, arginine/serine-rich 5 (SRp40, 1.48 y y 
HRS), Sfrs5 
1421063 s at small nuclear ribonucleoprotein N, Snrpn 1.46 y y 
1455696_a_at PRP4 pre-mRNA processing factor 4 homolog 1.43 N y 
B (yeast) , Prpf4b 
1454689 at serine/arginine repetitive matrix 1, Srrm1 1.42 y y 
1415807 _s_at splicing factor, arginine/serine-rich 2 (SC-35), 1.41 y y 
Sfrs2 
Signaling 
1424831 at copine II, Cpne2 , 4.94 y y 
1418572_x_at tumor necrosis factor receptor superfamily, 2.68 y y 
member 12a, Tnfrsf12a 
1428057 a at AHNAK nucleoprotein (desmoyokin), Ahnak 2.41 y y 
1416029 at Kruppel-like factor 10, Klf1 0 2.08 N y 
1425241 a at WD repeat and SOCS box-containing 1, Wsb1 1.83 y y 
1424613_at G protein-coupled receptor, family C, group 5, 1.79 y y 
member B, Gprc5b 
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1427005 at polo-like kinase 2 (Drosophila) , Plk2 1.79 y y 
1424542 at S100 calcium binding protein A4, S100a4 1.76 y y 
1436566_at Rab40b, member RAS oncogene family, 1.74 y y 
Rab40b 
1426465_;,at discs, large homolog_.associated protein 4 1.74 y y 
ll_Drosophila), Dlgap4 
1415712_at zinc finger, RAN-binding domain containing 1, 1.73 y y 
Zranb1 
1424176 a at annexin A4, Anxa4 1.72 y y 
1427006_at Rap guanine nucleotide exchange factor 1.69 y y 
1 
( GEF) 1, Rapgef1 
1426602_at v-raf murine sarcoma 3611 ·viral oncogene 1.64 y y 
homolog, Araf 
1454060 a at neuroblastoma ras oncog_ene, Nras 1.62 y y 
1422886 a at CDC like kinase 4, Clk4 1.62 N y 
1439962_at RIKEN eDNA 2310010J17 gene, 1.61 y y 
2310010J17Rik 
1430295_at guanine nucleotide binding protein , alpha 13, 1.61 y y 
Gna13 
1448582 at catenin, beta like 1, Ctnnbl1 1.59 y y 
1421321 a at neuroepithelial cell transforming gene 1, Net1 1.58 y y 
1428011 a at Erbb2 interacting protein , Erbb2ip 1.57 y y 
1418822 a at ADP-ribosylation factor 6, Arf6 1.57 y y 
1431428 a at nitric oxide synthase interacting protein, Nosip 1.56 y y 
1451063 at syntaxin binding protein 4, Stxbp4 1.56 y y 
1421324_a_at thymoma viral proto-oncogene 2 Ill similar to 1.55 y y 
serine/threonine kinase, Akt2 Ill 
LOC 1 00048123 
1434820 s at protein kinase inhibitor, gamma, Pkig 1.54 y y 
1424893_at nuclear distribution gene E-like homolog 1 (A. 1.53 y y 
nidulans), Ndel1 
1426044 a at protein kinase C, theta, Prkcq 1.48 y y 
1425202 a at ankyrin 3, epithelial , Ank3 1.46 N y 
1448676_at calcium/calmodulin-dependent protein kinase 1.45 y y 
II , beta, Camk2b 
1417398_at related RAS viral (r-ras) oncogene homolog 2, 1.44 y y 
Rras2 
Stress 
1449519_at growth arrest and DNA-damage-inducible 45 6.08 N y 
alpha, Gadd45a 
1416411 at !glutathione S-transferase, mu 2, Gstm2 2.74 N y 
1422557 s at metallothionein 1, Mt1 1.91 y y 
101 
Feature Gene Name, Gene ID FC p50 Bcl-3 
Structure 
target target 
1449533 at transmembrane protein 100, Tmem100 5.46 N y 
1435526 at torsin A interacting protein 2, Tor1 aip2 1.54 y y 
1430421 a at transmembrane protein 205, Tmem205 1.5 y y 
1434503_s_at lysosomal-associated membrane protein 2, 1.5 y y 
Lamp2 
1426628 at transmembrane protein 34, Tmem34 1.48 y y 
1455642 a at tetraspanin 17, Tspan17 1.43 y y 
1424354 at transmembrane protein 140, Tmem140 1.42 N y 
Transcription 
1420991_at ankyrin repeat domain 1 (cardiac muscle) , 7.93 N y 
Ankrd1 
1422864 at runt related transcription factor 1, runx1 5.26 y y 
1435458 at proviral integration site 1, Pim1 2.62 N y 
1426690_a_at sterol regulatory element binding transcription 2.42 y y 
factor 1 , Srebf1 
1449363 at activating transcription factor 3, Atf3 2.24 y y 
1448293 at early B-cell factor 1, Ebf1 1.71 y y 
1417409 at Jun oncogene, Jun 1.65 y y 
1449029_at MAP kinase-interacting serine/threonine 1.65 y y 
kinase 2, Mknk2 
1428467 at TAR DNA binding protein , Tardbp 1.64 N y 
1434037 s at ! p300/CBP-associated factor, Pcaf 1.63 y y 
1449800 x at PHD finger protein 7, Phf? 1.6 y y 
1426383_at cryptochrome 2 (photolyase-like) Ill similar to 1.54 y y 
mKIAA0658 protein, Cry2/// LOC100048334 
1455039 a at transcriptional regulator, SIN3B (yeast) , Sin3b 1.51 y y 
1451285_at fusion , derived from t(12;16) malignant 1.5 y y 
liposarcoma (human) , Fus 
1427162 a at ELK4, member of ETS oncogene family, Elk4 1.48 y y 
1454149 a at cyclin L2, Ccnl2 1.48 y y 
1423839 a at basic transcription factor 3, Btf3 1.45 y y 
1416630 at inhibitor of DNA binding 3, ld3 1.44 y y 
1420870_at myeloid/lymphoid or mixed-lineage leukemia 1.43 N y 
(trithorax homolog, Drosophila); translocated 
to, 1 0, Mllt1 0 
1415997 at thioredoxin interacting protein, Txnip 1.43 N y 
1422554 at necdin-like 2, Ndnl2 1.41 y y 
Translation 
1416332 at cold inducible RNA binding protein , Cirbp 2.71 y y 
1422660 at RNA binding motif protein 3, Rbm3 2.6 N y 
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1448325_at myeloid differentiation primary response gene 2.57 N y 
116, Myd116 
1434004 at deoxyhypusine synthase, Dhps 1.78 y y 
1423142 a at GTP binding protein 4, Gtpbp4 1.77 y y 
1439415 x at ribosomal protein S21 , Rps21 1.63 y y 
1434976_x_at eukaryotic translation initiation factor 4E 1.61 y y 
binding protein 1, Eif4ebp1 
1423254 x at ribosomal protein S27 -like, Rps271 1.57 y y 
1433631 at eukaryotic translation initiation factor 5, Eif5 1.52 N y 
1449323 a at ribosomal protein L3, Rpl3 1.51 y y 
1460171_at COP9 (constitutive photomorphogenic) 1.5 y y 
homolog, subunit 5 (Arabidopsis thaliana), 
Cops5 
1454664 a at eukaryotic translation initiation factor 5, Eif5 1.49 y y 
1435712 a at ribosomal protein S18, Rps18 1.48 y y 
1453467 s at ribosomal protein S15a, R_ps15a 1.47 y y 
1448472 at valyl-tRNA synthetase, Vars 1.47 y y 
1456083_x_at eukaryotic translation initiation factor 3, 1.46 y y 
subunit C, Eif3c 
1450506_a_at interferon stimulated exonuclease gene 20-like 1.46 y y 
1, lsg2011 
1438507 x at ribosomal protein L 14, Rp114 1.45 y y 
1455141 at trinucleotide repeat containing 6a, Tnrc6a 1.44 y y 
1418568 x at signal recognition particle 14, Srp14 1.43 y y 
1429453 a at mitochondrial ribosomal protein L55, Mrpl55 1.41 y y 
1448217 a at ribosomal protein L27, Rpl27 1.4 y y 
Transport 
1420884 at sarcolipin , Sin 20.89 N y 
1418852_at cholinergic receptor, nicotinic, alpha 3.32 N y 
polypeptide 1 (muscle) Ill similar to 
acetylcholine receptor alpha-subunit, Chrna1 
1421840_at ATP-binding cassette, sub-family A (ABC1), 2.83 N y 
member 1, Abca1 
1420682_at cholinergic receptor, nicotinic, beta 2.46 N y 
!polypeptide 1 (muscle), Chrnb1 
1416371 at apolipoprotein D, Apod 2.39 N y 
1434513 at ATPase type 13A3, Atp13a3 2.11 y y 
1448568 a at solute carrier family 20, member 1, Slc20a1 1.7 y y 
1449099 at LPS-responsive beige-like anchor, Lrba 1.69 N y 
1451665_a_at adaptor-related protein complex AP-4, sigma 1.67 y y 
1, Ap4s1 
1451130_at unconventional SNARE in the ER 1 homolog 1.63 y y 
I (S. cerevisiae), Use1 
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1422813_at calcium channel, voltage-dependent, gamma 1.62 y y 
subunit 1, Cacng 1 
1416138 at annexin A?, Anxa7 1.62 y y 
1423173_at N-ethylmaleimide sensitive fusion protein 1.57 N y 
attachment protein beta, Napb 
1423082 at Der1-like domain family, member 1, Derl1 1.56 y y 
1426344 at GLE1 RNA export mediator (yeast), Gle1 1.5 y y 
1438559 x at solute carrier family 44, member 2, Slc44a2 1.48 y y 
1434773_a_at solute carrier family 2 (facilitated glucose 1.42 y y 
transporter), member 1, Slc2a1 
1453063 at clathrin, light polypeptide (Lcb), Cltb 1.41 y y 
1418447_at golgi autoantigen, golgin subfamily a, 5, 1.4 y y 
Golga5 
Non-annotated genes or RIKEN eDNA 
1450013_at RIKEN eDNA 2900073G15 gene, 2.49 y y 
2900073G15Rik 
1420820_at RIKEN eDNA 2900073G15 gene, 2.07 y y 
2900073G15Rik 
1449629 s at Transcribed locus, --- 1.81 N y 
1417348_at RIKEN eDNA 2310039H08 gene, 1.71 y y 
231 0039H08Rik 
1433924 at Transcribed locus, --- 1.63 N y 
1435690_at RIKEN eDNA 2310008H09 gene, 1.62 y y 
231 0008H09Rik 
1434025 at Transcribed locus, --- 1.5 N y 
1436092 at Transcribed locus, --- 1.48 y y 
1435524 at CDNA clone IMAGE: 1196043, --- 1.48 N y 
1428317 at 1.47 y y 
1423947 _at RIKEN eDNA 1110008P14 gene, 1.45 y y 
1110008P14Rik 
1431712_a_at RIKEN eDNA 2310022A10 gene, 1.45 y y 
231 0022A 1 ORik 
1428529_at RIKEN eDNA 2810026P18 gene, 1.44 N y 
281 0026P18Rik 
1428515_at RIKEN eDNA 2410012H22 gene, 1.41 y y 
241 0012H22Rik 
FC indicates the fold change of gene expression due to h1nd limb unload1ng m wild-type 
animals from the microarray analysis. Y= a target gene for p50 or Bcl-3, N= not a target 
gene for p50 or Bcl-3. 
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